WO2018174288A1 - 2(1h)-キノリノン誘導体 - Google Patents
2(1h)-キノリノン誘導体 Download PDFInfo
- Publication number
- WO2018174288A1 WO2018174288A1 PCT/JP2018/011913 JP2018011913W WO2018174288A1 WO 2018174288 A1 WO2018174288 A1 WO 2018174288A1 JP 2018011913 W JP2018011913 W JP 2018011913W WO 2018174288 A1 WO2018174288 A1 WO 2018174288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- amino
- methyl
- substituted
- solution
- Prior art date
Links
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 268
- 150000003839 salts Chemical class 0.000 claims abstract description 60
- -1 1-amino-cyclobutan-3-yl group Chemical group 0.000 claims description 271
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 203
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 184
- 125000001424 substituent group Chemical group 0.000 claims description 67
- 229920006395 saturated elastomer Polymers 0.000 claims description 61
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 60
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 58
- 125000000623 heterocyclic group Chemical group 0.000 claims description 54
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 52
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 45
- 125000003277 amino group Chemical group 0.000 claims description 42
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 28
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 26
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 25
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 22
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 21
- 125000002757 morpholinyl group Chemical group 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000003386 piperidinyl group Chemical group 0.000 claims description 15
- 229910052720 vanadium Inorganic materials 0.000 claims description 15
- 125000004434 sulfur atom Chemical group 0.000 claims description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 11
- 125000004429 atom Chemical group 0.000 claims description 11
- 125000004193 piperazinyl group Chemical group 0.000 claims description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 9
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 9
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 8
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 6
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- 229940127266 GyrB and ParE Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N piperidine-4-one Natural products O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 claims 1
- 108010054814 DNA Gyrase Proteins 0.000 abstract description 22
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 108010041052 DNA Topoisomerase IV Proteins 0.000 abstract description 14
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 298
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 247
- 239000007787 solid Substances 0.000 description 158
- 238000006243 chemical reaction Methods 0.000 description 147
- 239000000203 mixture Substances 0.000 description 143
- 238000004458 analytical method Methods 0.000 description 136
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 135
- 230000002829 reductive effect Effects 0.000 description 129
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 118
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 117
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 88
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 88
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 87
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 86
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 82
- 239000012043 crude product Substances 0.000 description 82
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 76
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 75
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 75
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 72
- 239000000741 silica gel Substances 0.000 description 71
- 229910002027 silica gel Inorganic materials 0.000 description 71
- 238000004440 column chromatography Methods 0.000 description 68
- 239000007788 liquid Substances 0.000 description 67
- 238000005481 NMR spectroscopy Methods 0.000 description 64
- 238000004519 manufacturing process Methods 0.000 description 64
- 239000011541 reaction mixture Substances 0.000 description 62
- 238000002360 preparation method Methods 0.000 description 61
- 239000012044 organic layer Substances 0.000 description 59
- 238000001914 filtration Methods 0.000 description 58
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 58
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 53
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 46
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 46
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 46
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 42
- 235000017557 sodium bicarbonate Nutrition 0.000 description 42
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 39
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 238000000034 method Methods 0.000 description 29
- 238000012360 testing method Methods 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 238000001816 cooling Methods 0.000 description 26
- 239000000706 filtrate Substances 0.000 description 26
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 25
- 235000019270 ammonium chloride Nutrition 0.000 description 23
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 239000007821 HATU Substances 0.000 description 21
- 238000003756 stirring Methods 0.000 description 21
- 239000007864 aqueous solution Substances 0.000 description 20
- 239000002994 raw material Substances 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 14
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 14
- 239000012298 atmosphere Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 125000002950 monocyclic group Chemical group 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 239000002198 insoluble material Substances 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- JPKBGVUASYKITQ-UHFFFAOYSA-N 6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carboxylic acid Chemical compound C1=2C=C(C(=O)NC=2C(=CC(=C1)F)NC)C(=O)O JPKBGVUASYKITQ-UHFFFAOYSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 238000010791 quenching Methods 0.000 description 12
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 235000011054 acetic acid Nutrition 0.000 description 9
- GYBMSOFSBPZKCX-UHFFFAOYSA-N sodium;ethanol;ethanolate Chemical compound [Na+].CCO.CC[O-] GYBMSOFSBPZKCX-UHFFFAOYSA-N 0.000 description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 8
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- FTCVICNKERLUCN-UHFFFAOYSA-N methyl 2-amino-3-[benzyl(methyl)amino]-5-fluorobenzoate Chemical compound C1(C(=O)OC)=CC(F)=CC(N(CC2=CC=CC=C2)C)=C1N FTCVICNKERLUCN-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- FBGWTMVLPUNBHO-UHFFFAOYSA-N 3-[4-[(2-methylpropan-2-yl)oxycarbonyl]anilino]-3-oxopropanoic acid Chemical compound C(OC(=O)C1=CC=C(NC(=O)CC(=O)O)C=C1)(C)(C)C FBGWTMVLPUNBHO-UHFFFAOYSA-N 0.000 description 6
- AMKYQHPMDUYSMR-UHFFFAOYSA-N 8-(methylamino)-2-oxo-1H-quinoline-3-carboxylic acid Chemical compound CNC=1C=CC=C2C=C(C(NC=12)=O)C(=O)O AMKYQHPMDUYSMR-UHFFFAOYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000001340 alkali metals Chemical class 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 6
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- LDYNFUZEZIQYKC-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methoxy]-8-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-1,6-naphthyridine-3-carboxylic acid Chemical compound C1=C(C(=NC2=C1C=NC=C2N(C(=O)OC(C)(C)C)C)OCC1=CC=C(OC)C=C1)C(=O)O LDYNFUZEZIQYKC-UHFFFAOYSA-N 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
- 150000008065 acid anhydrides Chemical class 0.000 description 5
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- 229940124350 antibacterial drug Drugs 0.000 description 5
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 5
- 125000005605 benzo group Chemical group 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000000752 ionisation method Methods 0.000 description 5
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 5
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 101710183280 Topoisomerase Proteins 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000000105 evaporative light scattering detection Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 4
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 3
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 3
- OZMLUMPWPFZWTP-UHFFFAOYSA-N 2-(tributyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CCCCP(CCCC)(CCCC)=CC#N OZMLUMPWPFZWTP-UHFFFAOYSA-N 0.000 description 3
- AVLAOZUSUYWMEZ-UHFFFAOYSA-N 3-[N-[(2,4-dimethoxyphenyl)methyl]-4-[(2-methylpropan-2-yl)oxycarbonyl]anilino]-3-oxopropanoic acid Chemical compound C(OC(=O)C1=CC=C(N(C(=O)CC(=O)O)CC2=C(OC)C=C(OC)C=C2)C=C1)(C)(C)C AVLAOZUSUYWMEZ-UHFFFAOYSA-N 0.000 description 3
- QDCKNWASTDDVRR-UHFFFAOYSA-N 4-[[6-fluoro-8-(methylamino)-2-oxo-1H-quinolin-3-yl]methylamino]benzoic acid Chemical compound C1=C(C=CC(=C1)NCC=1C(=O)NC2=C(C=C(F)C=C2C=1)NC)C(=O)O QDCKNWASTDDVRR-UHFFFAOYSA-N 0.000 description 3
- INCGNCLHLBZBSL-DUXPYHPUSA-N 4-[[6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]-3-[(E)-4-hydroxybut-1-enyl]benzoic acid Chemical compound C(C/C=C/C1=C(NC(=O)C2=CC3=C(C(=CC(F)=C3)NC)NC2=O)C=CC(C(=O)O)=C1)O INCGNCLHLBZBSL-DUXPYHPUSA-N 0.000 description 3
- AKYNSXWXXVNOGT-UHFFFAOYSA-N 4-[[8-[benzyl(methyl)amino]-6-fluoro-4-hydroxy-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid Chemical compound C1=CC(=CC=C1NC(=O)C1=C(C2=CC(F)=CC(N(CC3=CC=CC=C3)C)=C2NC1=O)O)C(=O)O AKYNSXWXXVNOGT-UHFFFAOYSA-N 0.000 description 3
- WDXSFWKQZLHFET-UHFFFAOYSA-N 6-fluoro-2-[(4-methoxyphenyl)methoxy]-8-(methylamino)quinoline-3-carbaldehyde Chemical compound C1(C=O)=CC2=CC(F)=CC(NC)=C2N=C1OCC1=CC=C(OC)C=C1 WDXSFWKQZLHFET-UHFFFAOYSA-N 0.000 description 3
- KTEUQUFMZXSODZ-UHFFFAOYSA-N 6-fluoro-N-[4-(hydroxymethyl)pyridin-3-yl]-8-(methylamino)-2-oxo-1H-quinoline-3-carboxamide Chemical compound C(C1=C(NC(=O)C2=CC3=CC(F)=CC(NC)=C3NC2=O)C=NC=C1)O KTEUQUFMZXSODZ-UHFFFAOYSA-N 0.000 description 3
- LZKCIPJVXUZCQC-UHFFFAOYSA-N 7-fluoro-5-(methylamino)-3-oxo-4H-quinoxaline-2-carboxylic acid Chemical compound N1=C(C(=O)NC2=C(C=C(F)C=C12)NC)C(=O)O LZKCIPJVXUZCQC-UHFFFAOYSA-N 0.000 description 3
- VNARGCJFRXPMOC-UHFFFAOYSA-N 8-(methylamino)-2-oxo-1H-1,7-naphthyridine-3-carboxylic acid Chemical compound C1=C(C(=O)NC2=C1C=CN=C2NC)C(=O)O VNARGCJFRXPMOC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-DEGSGYPDSA-N [[(2s,3r,4s,5s)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1O[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@H](O)[C@@H]1O ZKHQWZAMYRWXGA-DEGSGYPDSA-N 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- HYSYYUAZZWGTGX-UHFFFAOYSA-N methyl 3-[benzyl(methyl)amino]-5-fluoro-2-nitrobenzoate Chemical compound C(C1=CC=CC=C1)N(C=1C(=C(C(=O)OC)C=C(C=1)F)[N+](=O)[O-])C HYSYYUAZZWGTGX-UHFFFAOYSA-N 0.000 description 3
- 229910000487 osmium oxide Inorganic materials 0.000 description 3
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 3
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 3
- JIWAALDUIFCBLV-UHFFFAOYSA-N oxoosmium Chemical compound [Os]=O JIWAALDUIFCBLV-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- UJPMYEOUBPIPHQ-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound CC(F)(F)F UJPMYEOUBPIPHQ-UHFFFAOYSA-N 0.000 description 2
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 2
- WWKXPHGKEMVOBX-UHFFFAOYSA-N 1-[3-[benzyl(methyl)amino]-5-fluoro-2-nitrophenyl]but-3-en-1-ol Chemical compound C(C1=CC=CC=C1)N(C=1C(=C(C=C(C=1)F)C(CC=C)O)[N+](=O)[O-])C WWKXPHGKEMVOBX-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
- LWRSYTXEQUUTKW-UHFFFAOYSA-N 2,4-dimethoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(OC)=C1 LWRSYTXEQUUTKW-UHFFFAOYSA-N 0.000 description 2
- IFLZQUGDORTWLC-UHFFFAOYSA-N 2-amino-5-fluoro-3-(methylamino)benzaldehyde Chemical compound C1(C=O)=CC(F)=CC(NC)=C1N IFLZQUGDORTWLC-UHFFFAOYSA-N 0.000 description 2
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 2
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 2
- PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical compound O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 description 2
- XIEXWBLDZCPBKV-UHFFFAOYSA-N 3-(2-iodo-4-methoxycarbonylanilino)-3-oxopropanoic acid Chemical compound C1=C(C=CC(=C1I)NC(=O)CC(=O)O)C(=O)OC XIEXWBLDZCPBKV-UHFFFAOYSA-N 0.000 description 2
- VYNUIEHNFKAEEV-UHFFFAOYSA-N 3-(chloromethyl)-6-fluoro-8-(methylamino)-1H-quinolin-2-one Chemical compound FC1=CC(NC)=C2NC(=O)C(CCl)=CC2=C1 VYNUIEHNFKAEEV-UHFFFAOYSA-N 0.000 description 2
- OKUMYQPHLBJRJD-UHFFFAOYSA-N 3-N-benzyl-5-fluoro-3-N-methyl-2-nitrobenzene-1,3-diamine Chemical compound C(C1=CC=CC=C1)N(C1=C(C(=CC(=C1)F)N)[N+](=O)[O-])C OKUMYQPHLBJRJD-UHFFFAOYSA-N 0.000 description 2
- JLFIYLKWNWEURE-UHFFFAOYSA-N 3-N-benzyl-5-fluoro-3-N-methylbenzene-1,2,3-triamine Chemical compound FC1=CC(N(CC2=CC=CC=C2)C)=C(N)C(N)=C1 JLFIYLKWNWEURE-UHFFFAOYSA-N 0.000 description 2
- NGGGZUAEOKRHMA-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxy]-3-oxopropanoic acid Chemical compound CC(C)(C)OC(=O)CC(O)=O NGGGZUAEOKRHMA-UHFFFAOYSA-N 0.000 description 2
- PMCIJZUEAJRSPK-UHFFFAOYSA-N 3-[(3-aminopiperidin-1-yl)methyl]-4-[[6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid hydrochloride Chemical compound Cl.NC1CN(CCC1)CC=1C=C(C(=O)O)C=CC1NC(=O)C=1C(NC2=C(C=C(C=C2C1)F)NC)=O PMCIJZUEAJRSPK-UHFFFAOYSA-N 0.000 description 2
- KQZRWCBIVRJQCR-UHFFFAOYSA-N 3-[(8-amino-2-oxo-1H-quinoline-3-carbonyl)amino]benzoic acid 2,2,2-trifluoroacetic acid Chemical compound C1=CC(=CC(=C1)NC(=O)C2=CC3=C(C(=CC=C3)N)NC2=O)C(=O)O.C(=O)(C(F)(F)F)O KQZRWCBIVRJQCR-UHFFFAOYSA-N 0.000 description 2
- DERJUWIDNIZOET-UHFFFAOYSA-N 3-[(8-nitro-2-oxo-1H-quinoline-3-carbonyl)amino]benzoic acid Chemical compound [N+](=O)([O-])C=1C=CC=C2C=C(C(NC=12)=O)C(=O)NC=1C=C(C(=O)O)C=CC=1 DERJUWIDNIZOET-UHFFFAOYSA-N 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- LSBOCTBKCTWPLR-UHFFFAOYSA-N 3-[3-[benzyl(methyl)amino]-5-fluoro-2-nitrophenyl]-3-[tert-butyl(dimethyl)silyl]oxypropanal Chemical compound C(C1=CC=CC=C1)N(C=1C(=C(C=C(C=1)F)C(CC=O)O[Si](C)(C)C(C)(C)C)[N+](=O)[O-])C LSBOCTBKCTWPLR-UHFFFAOYSA-N 0.000 description 2
- IDUOLSWKOHPWTI-UHFFFAOYSA-N 3-[4-methoxycarbonyl-2-(morpholin-4-ylmethyl)anilino]-3-oxopropanoic acid Chemical compound C1N(CCOC1)CC1=C(NC(=O)CC(=O)O)C=CC(C(=O)OC)=C1 IDUOLSWKOHPWTI-UHFFFAOYSA-N 0.000 description 2
- YSERSASIIDQYQM-UHFFFAOYSA-N 3-[[8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid Chemical compound CNC=1C=CC=C2C=C(C(NC=12)=O)C(=O)NC=1C=C(C(=O)O)C=CC=1 YSERSASIIDQYQM-UHFFFAOYSA-N 0.000 description 2
- LIEZBZQSBSCDEI-UHFFFAOYSA-N 3-[[cyclohexyl(methyl)amino]methyl]-4-[[7-fluoro-5-(methylamino)-3-oxo-4H-quinoxaline-2-carbonyl]amino]benzoic acid Chemical compound C1CCC(N(C)CC2=CC(=CC=C2NC(=O)C2=NC3=C(C(=CC(F)=C3)NC)NC2=O)C(=O)O)CC1 LIEZBZQSBSCDEI-UHFFFAOYSA-N 0.000 description 2
- PAKHQPMISWDEMA-UHFFFAOYSA-N 3-[[cyclohexyl(methyl)amino]methyl]-4-[[8-(methylamino)-2-oxo-1H-1,6-naphthyridine-3-carbonyl]amino]benzoic acid Chemical compound C1CC(N(C)CC2=CC(=CC=C2NC(=O)C2=CC3=CN=CC(=C3NC2=O)NC)C(=O)O)CCC1 PAKHQPMISWDEMA-UHFFFAOYSA-N 0.000 description 2
- NVYKSAWPYZFNRP-UHFFFAOYSA-N 3-[cyclohexyl(methyl)amino]-4-[[6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid Chemical compound C1(N(C2=CC(=CC=C2NC(=O)C2=CC3=CC(F)=CC(NC)=C3NC2=O)C(=O)O)C)CCCCC1 NVYKSAWPYZFNRP-UHFFFAOYSA-N 0.000 description 2
- UVEWLZDVIMVFJG-UHFFFAOYSA-N 3-amino-2-[benzyl(methyl)amino]pyridine-4-carbaldehyde Chemical compound C(=O)C1=CC=NC(N(CC2=CC=CC=C2)C)=C1N UVEWLZDVIMVFJG-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- AVMQFAMOUWYIAW-UHFFFAOYSA-N 4-[(2-oxo-1H-quinoline-3-carbonyl)amino]benzoic acid Chemical compound O=C1NC2=CC=CC=C2C=C1C(=O)NC1=CC=C(C(=O)O)C=C1 AVMQFAMOUWYIAW-UHFFFAOYSA-N 0.000 description 2
- CIQKJFPQUHAMKO-UHFFFAOYSA-N 4-[(8-hydroxy-2-oxo-1H-quinoline-3-carbonyl)amino]benzoic acid Chemical compound OC=1C=CC=C2C=C(C(NC=12)=O)C(=O)NC1=CC=C(C(=O)O)C=C1 CIQKJFPQUHAMKO-UHFFFAOYSA-N 0.000 description 2
- SDGJYOXNCZUNMI-UHFFFAOYSA-N 4-[(8-methoxy-2-oxo-1H-quinoline-3-carbonyl)amino]benzoic acid Chemical compound COC=1C=CC=C2C=C(C(NC=12)=O)C(=O)NC1=CC=C(C(=O)O)C=C1 SDGJYOXNCZUNMI-UHFFFAOYSA-N 0.000 description 2
- RMIKNWZXDUVYEQ-UHFFFAOYSA-N 4-[3-[benzyl(methyl)amino]-5-fluoro-2-nitrophenyl]-4-[tert-butyl(dimethyl)silyl]oxybutanal Chemical compound C(C1=CC=CC=C1)N(C=1C(=C(C=C(C=1)F)C(CCC=O)O[Si](C)(C)C(C)(C)C)[N+](=O)[O-])C RMIKNWZXDUVYEQ-UHFFFAOYSA-N 0.000 description 2
- UQKWTSLOIULUON-UHFFFAOYSA-N 4-[[6-fluoro-4-hydroxy-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]-3-(morpholin-4-ylmethyl)benzoic acid Chemical compound C1CN(CCO1)CC1=C(NC(=O)C2=C(C3=CC(F)=CC(NC)=C3NC2=O)O)C=CC(C(=O)O)=C1 UQKWTSLOIULUON-UHFFFAOYSA-N 0.000 description 2
- ACSDSFPAGHERCC-UHFFFAOYSA-N 4-[[6-fluoro-4-hydroxy-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid Chemical compound C1=C(C=CC(=C1)NC(=O)C1=C(C2=CC(F)=CC(NC)=C2NC1=O)O)C(=O)O ACSDSFPAGHERCC-UHFFFAOYSA-N 0.000 description 2
- LBWAWJBTBLSGGR-UHFFFAOYSA-N 4-[[6-fluoro-4-methoxy-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid Chemical compound C1=C(C(=O)O)C=CC(=C1)NC(=O)C1=C(OC)C2=CC(F)=CC(NC)=C2NC1=O LBWAWJBTBLSGGR-UHFFFAOYSA-N 0.000 description 2
- MNOFCWGCCAMAFG-UHFFFAOYSA-N 4-[[6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]-3-(4-hydroxybutyl)benzoic acid Chemical compound C(CC1=C(NC(=O)C2=CC3=CC(F)=CC(NC)=C3NC2=O)C=CC(C(=O)O)=C1)CCO MNOFCWGCCAMAFG-UHFFFAOYSA-N 0.000 description 2
- DFAPUBLMKMWKJW-UHFFFAOYSA-N 4-[[6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid Chemical compound C1=C(C=CC(=C1)NC(=O)C1=CC2=CC(F)=CC(NC)=C2NC1=O)C(=O)O DFAPUBLMKMWKJW-UHFFFAOYSA-N 0.000 description 2
- MPMRKSVMQBLTPN-UHFFFAOYSA-N 4-[[8-(methylamino)-2-oxo-1H-1,7-naphthyridine-3-carbonyl]amino]benzoic acid Chemical compound C1(C(=O)O)=CC=C(NC(=O)C2=CC3=CC=NC(NC)=C3NC2=O)C=C1 MPMRKSVMQBLTPN-UHFFFAOYSA-N 0.000 description 2
- FCIPLSVRDYIFTM-UHFFFAOYSA-N 4-amino-1-[5-[[8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]pyrimidin-2-yl]piperidine-4-carboxylic acid hydrochloride Chemical compound Cl.NC1(CCN(CC1)C1=NC=C(C=N1)NC(=O)C=1C(NC2=C(C=CC=C2C=1)NC)=O)C(=O)O FCIPLSVRDYIFTM-UHFFFAOYSA-N 0.000 description 2
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- ZTLWUFVREYDLAR-UHFFFAOYSA-N 5-[[6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]pyrimidine-2-carboxylic acid Chemical compound N1=C(N=CC(NC(=O)C2=CC3=C(C(=CC(F)=C3)NC)NC2=O)=C1)C(=O)O ZTLWUFVREYDLAR-UHFFFAOYSA-N 0.000 description 2
- JHKVGAZXCVFQCJ-UHFFFAOYSA-N 5-fluoro-3-(methylamino)-2-nitrobenzaldehyde Chemical compound FC=1C=C(C(=C(C=O)C=1)[N+](=O)[O-])NC JHKVGAZXCVFQCJ-UHFFFAOYSA-N 0.000 description 2
- WAMLWOAPDGNCBW-UHFFFAOYSA-N 6-fluoro-4-hydroxy-8-(methylamino)-N-[4-(methylsulfonylcarbamoyl)phenyl]-2-oxo-1H-quinoline-3-carboxamide Chemical compound S(=O)(=O)(C)NC(=O)C1=CC=C(NC(=O)C2=C(C3=CC(F)=CC(NC)=C3NC2=O)O)C=C1 WAMLWOAPDGNCBW-UHFFFAOYSA-N 0.000 description 2
- XCEMSJHXVGITCV-UHFFFAOYSA-N 6-fluoro-8-(methylamino)-2-oxo-N-(2-piperazin-1-ylpyrimidin-5-yl)-1H-quinoline-3-carboxamide hydrochloride Chemical compound Cl.FC=1C=C2C=C(C(NC2=C(C1)NC)=O)C(=O)NC=1C=NC(=NC1)N1CCNCC1 XCEMSJHXVGITCV-UHFFFAOYSA-N 0.000 description 2
- IZXVZFALQISWLB-UHFFFAOYSA-N 6-fluoro-N-[2-(2-hydroxyethylcarbamoyl)pyrimidin-5-yl]-8-(methylamino)-2-oxo-1H-quinoline-3-carboxamide Chemical compound N1=C(N=CC(=C1)NC(=O)C1=CC2=CC(F)=CC(NC)=C2NC1=O)C(=O)NCCO IZXVZFALQISWLB-UHFFFAOYSA-N 0.000 description 2
- RSEYWKNLZMUFJP-UHFFFAOYSA-N 6-fluoro-N-[4-(hydroxycarbamoyl)phenyl]-8-(methylamino)-2-oxo-1H-quinoline-3-carboxamide Chemical compound C1=C(C=CC(=C1)NC(=O)C1=CC2=C(C(=CC(F)=C2)NC)NC1=O)C(=O)NO RSEYWKNLZMUFJP-UHFFFAOYSA-N 0.000 description 2
- DWYCNLPZNMQTAI-UHFFFAOYSA-N 8-(ethylamino)-1H-quinolin-2-one Chemical compound C(C)NC=1C=CC=C2C=CC(NC=12)=O DWYCNLPZNMQTAI-UHFFFAOYSA-N 0.000 description 2
- OKPIUMPWRDLTGX-UHFFFAOYSA-N 8-[benzyl(methyl)amino]-N-(4-carbamoylphenyl)-6-fluoro-4-hydroxy-2-oxo-1H-quinoline-3-carboxamide Chemical compound C1=C(C=CC(=C1)NC(=O)C1=C(C2=CC(F)=CC(N(CC3=CC=CC=C3)C)=C2NC1=O)O)C(=O)N OKPIUMPWRDLTGX-UHFFFAOYSA-N 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- UFJDQOQGSXVYRQ-UHFFFAOYSA-N C(=O)O.NCCCOC1=C(C(=O)O)C=CC(=C1)NC(=O)C=1C(NC2=C(C=C(C=C2C1)F)NC)=O Chemical compound C(=O)O.NCCCOC1=C(C(=O)O)C=CC(=C1)NC(=O)C=1C(NC2=C(C=C(C=C2C1)F)NC)=O UFJDQOQGSXVYRQ-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- ATEZAHQVOPFCJE-UHFFFAOYSA-N N-(4-carbamimidoylphenyl)-6-fluoro-4-hydroxy-8-(methylamino)-2-oxo-1H-quinoline-3-carboxamide Chemical compound C1(C(=N)N)=CC=C(NC(=O)C2=C(C3=CC(F)=CC(NC)=C3NC2=O)O)C=C1 ATEZAHQVOPFCJE-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- MEUOQTHGJMBRPV-UHFFFAOYSA-N N-[2-[(2-amino-1,3-thiazol-4-yl)methylamino]pyrimidin-5-yl]-8-(methylamino)-2-oxo-1H-quinoline-3-carboxamide Chemical compound C(NC1=NC=C(C=N1)NC(=O)C1=CC2=CC=CC(NC)=C2NC1=O)C=1N=C(SC=1)N MEUOQTHGJMBRPV-UHFFFAOYSA-N 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- QKFCNXBSRSLFMS-UHFFFAOYSA-N [5-fluoro-3-(methylamino)-2-nitrophenyl]methanol Chemical compound C1(F)=CC(NC)=C([N+](=O)[O-])C(CO)=C1 QKFCNXBSRSLFMS-UHFFFAOYSA-N 0.000 description 2
- KMYGVRPNARNGGJ-UHFFFAOYSA-N [6-fluoro-2-[(4-methoxyphenyl)methoxy]-8-(methylamino)quinolin-3-yl]methanol Chemical compound FC1=CC(NC)=C2N=C(OCC3=CC=C(OC)C=C3)C(CO)=CC2=C1 KMYGVRPNARNGGJ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- YEVZWRHABAFJOI-UHFFFAOYSA-N ethyl 2-[(4-methoxyphenyl)methoxy]-8-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-1,6-naphthyridine-3-carboxylate Chemical compound C1=C(C(=NC2=C1C=NC=C2N(C(=O)OC(C)(C)C)C)OCC1=CC=C(OC)C=C1)C(=O)OCC YEVZWRHABAFJOI-UHFFFAOYSA-N 0.000 description 2
- INLNOZUVQCQGHF-UHFFFAOYSA-N ethyl 5-[benzyl(methyl)amino]-7-fluoro-3-oxo-4H-quinoxaline-2-carboxylate Chemical compound N1=C(C(=O)NC2=C(C=C(F)C=C12)N(CC1=CC=CC=C1)C)C(=O)OCC INLNOZUVQCQGHF-UHFFFAOYSA-N 0.000 description 2
- UQCSLKXZPYFLNE-UHFFFAOYSA-N ethyl 6-fluoro-2-[(4-methoxyphenyl)methoxy]-8-(methylamino)quinoline-3-carboxylate Chemical compound C1=C(C(=NC2=C1C=C(F)C=C2NC)OCC1=CC=C(OC)C=C1)C(=O)OCC UQCSLKXZPYFLNE-UHFFFAOYSA-N 0.000 description 2
- IAJARORZEZLXDE-UHFFFAOYSA-N ethyl 7-fluoro-5-(methylamino)-3-oxo-2,4-dihydro-1H-quinoxaline-2-carboxylate Chemical compound C1(NC2=C(NC1=O)C(=CC(F)=C2)NC)C(=O)OCC IAJARORZEZLXDE-UHFFFAOYSA-N 0.000 description 2
- ZDMPENUYWSOAIX-UHFFFAOYSA-N ethyl 7-fluoro-5-(methylamino)-3-oxo-4H-quinoxaline-2-carboxylate Chemical compound N1=C(C(=O)NC2=C(NC)C=C(F)C=C12)C(=O)OCC ZDMPENUYWSOAIX-UHFFFAOYSA-N 0.000 description 2
- WTYCCWZXEYXLMI-UHFFFAOYSA-N ethyl 8-(methylamino)-2-oxo-1H-1,7-naphthyridine-3-carboxylate Chemical compound C1=2C=C(C(=O)NC=2C(=NC=C1)NC)C(=O)OCC WTYCCWZXEYXLMI-UHFFFAOYSA-N 0.000 description 2
- QOGLFHXAYMEEBY-UHFFFAOYSA-N ethyl 8-(methylamino)-2-oxo-1H-quinoline-3-carboxylate Chemical compound C1=C(C(=O)NC2=C1C=CC=C2NC)C(=O)OCC QOGLFHXAYMEEBY-UHFFFAOYSA-N 0.000 description 2
- BFUGFAGHMATFFO-UHFFFAOYSA-N ethyl 8-[benzyl(methyl)amino]-2-oxo-1H-1,7-naphthyridine-3-carboxylate Chemical compound C1=C(C(=O)NC2=C1C=CN=C2N(CC1=CC=CC=C1)C)C(=O)OCC BFUGFAGHMATFFO-UHFFFAOYSA-N 0.000 description 2
- RZYMWJQHCVJTGJ-UHFFFAOYSA-N ethyl 8-iodo-2-[(4-methoxyphenyl)methoxy]-1,6-naphthyridine-3-carboxylate Chemical compound C1=C(C(=NC2=C1C=NC=C2I)OCC1=CC=C(OC)C=C1)C(=O)OCC RZYMWJQHCVJTGJ-UHFFFAOYSA-N 0.000 description 2
- OKSFPJXNZQIMKZ-UHFFFAOYSA-N ethyl 8-iodo-2-oxo-1H-1,6-naphthyridine-3-carboxylate Chemical compound C1=C(C(=O)NC2=C1C=NC=C2I)C(=O)OCC OKSFPJXNZQIMKZ-UHFFFAOYSA-N 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- 101150070420 gyrA gene Proteins 0.000 description 2
- 101150013736 gyrB gene Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- CEAJFNBWKBTRQE-UHFFFAOYSA-N methanamine;methanol Chemical compound NC.OC CEAJFNBWKBTRQE-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- VZDNXXPBYLGWOS-UHFFFAOYSA-N methyl 3-aminobenzoate Chemical compound COC(=O)C1=CC=CC(N)=C1 VZDNXXPBYLGWOS-UHFFFAOYSA-N 0.000 description 2
- TWULGGYPGGCEMZ-UHFFFAOYSA-N methyl 3-ethenyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]benzoate Chemical compound C(=C)C1=C(NC(=O)OC(C)(C)C)C=CC(C(=O)OC)=C1 TWULGGYPGGCEMZ-UHFFFAOYSA-N 0.000 description 2
- MUFSZUGEXRADCL-UHFFFAOYSA-N methyl 3-formyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]benzoate Chemical compound COC(=O)C1=CC=C(NC(=O)OC(C)(C)C)C(C=O)=C1 MUFSZUGEXRADCL-UHFFFAOYSA-N 0.000 description 2
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000005479 oxodihydropyridyl group Chemical group 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- KYLUAQBYONVMCP-UHFFFAOYSA-N (2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P KYLUAQBYONVMCP-UHFFFAOYSA-N 0.000 description 1
- KZQNMHJNCFINIV-UHFFFAOYSA-N (3,5-difluoro-2-nitrophenyl)methanol Chemical compound OCC1=CC(F)=CC(F)=C1[N+]([O-])=O KZQNMHJNCFINIV-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- OQZQXOFJGSSYNX-UHFFFAOYSA-N 1,2-dihydroquinoline-3-carboxamide Chemical compound C1=CC=C2NCC(C(=O)N)=CC2=C1 OQZQXOFJGSSYNX-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- LNUDOSLAIDZLGW-UHFFFAOYSA-L 1,3-bis[2,6-di(propan-2-yl)phenyl]imidazolidin-2-ide;3-chloropyridine;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].ClC1=CC=CN=C1.CC(C)C1=CC=CC(C(C)C)=C1N1[CH-]N(C=2C(=CC=CC=2C(C)C)C(C)C)CC1 LNUDOSLAIDZLGW-UHFFFAOYSA-L 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- KQMZWFMBUAKXAO-UHFFFAOYSA-N 1-[5-[[8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]pyrimidin-2-yl]-4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-4-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)NC1(CCN(CC1)C1=NC=C(C=N1)NC(=O)C=1C(NC2=C(C=CC=C2C=1)NC)=O)C(=O)O KQMZWFMBUAKXAO-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- MTVBBLNLYSYKCQ-UHFFFAOYSA-N 2-[[cyclohexyl(methyl)amino]methyl]aniline Chemical compound C1CCCCC1N(C)CC1=CC=CC=C1N MTVBBLNLYSYKCQ-UHFFFAOYSA-N 0.000 description 1
- JDTCLPRXHCOVMY-UHFFFAOYSA-N 2-amino-3-(methylamino)benzaldehyde Chemical compound NC1=C(C=O)C=CC=C1NC JDTCLPRXHCOVMY-UHFFFAOYSA-N 0.000 description 1
- GDIYDPBHVKDDIR-UHFFFAOYSA-N 2-amino-3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1N GDIYDPBHVKDDIR-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- JUPIBUVTFBCMRW-UHFFFAOYSA-N 2-n-benzyl-2-n-methylpyridine-2,3-diamine Chemical compound N=1C=CC=C(N)C=1N(C)CC1=CC=CC=C1 JUPIBUVTFBCMRW-UHFFFAOYSA-N 0.000 description 1
- NMMRJEQSSYGBTR-UHFFFAOYSA-N 2-oxo-1H-quinoline-8-carbaldehyde Chemical compound C1=CC=C(C=O)C2=NC(O)=CC=C21 NMMRJEQSSYGBTR-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ZULNIHUDSFLCBT-UHFFFAOYSA-N 3,5-difluoro-2-nitroaniline Chemical compound NC1=CC(F)=CC(F)=C1[N+]([O-])=O ZULNIHUDSFLCBT-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- MPLCAWUZLDZLOG-UHFFFAOYSA-N 3-(4-ethoxycarbonylanilino)-3-oxopropanoic acid Chemical compound CCOC(=O)C1=CC=C(NC(=O)CC(O)=O)C=C1 MPLCAWUZLDZLOG-UHFFFAOYSA-N 0.000 description 1
- ZTJZCGYKOZBYJK-UHFFFAOYSA-N 3-[[cyclohexyl(methyl)amino]methyl]-4-[[6-fluoro-8-(methylamino)-2-oxo-1H-quinolin-3-yl]methylamino]benzoic acid Chemical compound C1CCC(N(CC2=C(NCC=3C(=O)NC4=C(C=C(C=C4C=3)F)NC)C=CC(C(=O)O)=C2)C)CC1 ZTJZCGYKOZBYJK-UHFFFAOYSA-N 0.000 description 1
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- HFLQWWZFZIVCGB-UHFFFAOYSA-N 3-chloro-N-ethyl-2-nitroaniline Chemical compound ClC=1C(=C(NCC)C=CC=1)[N+](=O)[O-] HFLQWWZFZIVCGB-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- CKXLYMUOAILRTI-UHFFFAOYSA-N 4-[3-[benzyl(methyl)amino]-5-fluoro-2-nitrophenyl]-4-[tert-butyl(dimethyl)silyl]oxybutan-1-ol Chemical compound C(C1=CC=CC=C1)N(C=1C(=C(C=C(C=1)F)C(CCCO)O[Si](C)(C)C(C)(C)C)[N+](=O)[O-])C CKXLYMUOAILRTI-UHFFFAOYSA-N 0.000 description 1
- NNLNDKUMTATEBI-UHFFFAOYSA-N 4-[[4-(2-aminoethylamino)-6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid Chemical compound CNC1=CC(=CC2=C1NC(=O)C(=C2NCCN)C(=O)NC3=CC=C(C=C3)C(=O)O)F NNLNDKUMTATEBI-UHFFFAOYSA-N 0.000 description 1
- OKMNLGYEUYGHKX-UHFFFAOYSA-N 4-[[4-(2-aminoethylamino)-6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid formic acid Chemical compound CNC1=CC(F)=CC(C(NCCN)=C2C(NC(C=C3)=CC=C3C(O)=O)=O)=C1NC2=O.OC=O OKMNLGYEUYGHKX-UHFFFAOYSA-N 0.000 description 1
- DLENIPUURLUPKZ-UHFFFAOYSA-N 4-[[6-fluoro-4-methoxy-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]-(2,2,2-trifluoroacetyl)amino]benzoic acid Chemical compound C1=C(C(=O)O)C=CC(=C1)N(C(=O)C1=C(OC)C2=CC(F)=CC(NC)=C2NC1=O)C(=O)C(F)(F)F DLENIPUURLUPKZ-UHFFFAOYSA-N 0.000 description 1
- JOBDMCGXYWNNRK-UHFFFAOYSA-N 4-[[6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carbonyl]amino]-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]benzoic acid Chemical compound C(=O)(OC(C)(C)C)NCCCOC1=CC(NC(=O)C2=CC3=CC(F)=CC(NC)=C3NC2=O)=CC=C1C(=O)O JOBDMCGXYWNNRK-UHFFFAOYSA-N 0.000 description 1
- ZQPFFMNJTDZTRE-UHFFFAOYSA-N 4-[[6-fluoro-8-(methylamino)-4-[2-(methylamino)ethyl]-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid Chemical compound C(CC=1C2=CC(F)=CC(NC)=C2NC(=O)C=1C(=O)NC1=CC=C(C=C1)C(=O)O)NC ZQPFFMNJTDZTRE-UHFFFAOYSA-N 0.000 description 1
- KJRBCQYYGDCLJF-UHFFFAOYSA-N 4-[[6-fluoro-8-(methylamino)-4-[2-(methylamino)ethyl]-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.FC=1C=C2C(=C(C(NC2=C(C=1)NC)=O)C(=O)NC1=CC=C(C(=O)O)C=C1)CCNC KJRBCQYYGDCLJF-UHFFFAOYSA-N 0.000 description 1
- KWWCVIYXWVWFML-UHFFFAOYSA-N 4-[[6-fluoro-8-(methylamino)-4-[3-(methylamino)propyl]-2-oxo-1H-quinoline-3-carbonyl]amino]benzoic acid 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.FC=1C=C2C(=C(C(NC2=C(C1)NC)=O)C(=O)NC1=CC=C(C(=O)O)C=C1)CCCNC KWWCVIYXWVWFML-UHFFFAOYSA-N 0.000 description 1
- OBTQKZSCIDELLN-UHFFFAOYSA-N 4-amino-n-(2-morpholin-4-ylethyl)benzamide Chemical compound C1=CC(N)=CC=C1C(=O)NCCN1CCOCC1 OBTQKZSCIDELLN-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- VGVAMHFYVABFJZ-UHFFFAOYSA-N 6-fluoro-3-(hydroxymethyl)-8-(methylamino)-1H-quinolin-2-one Chemical compound FC=1C=C2C=C(C(NC2=C(C=1)NC)=O)CO VGVAMHFYVABFJZ-UHFFFAOYSA-N 0.000 description 1
- WXHGTUVYWLEYAR-UHFFFAOYSA-N 6-fluoro-8-(methylamino)-2-oxo-N-pyrimidin-5-yl-1H-quinoline-3-carboxamide Chemical compound FC=1C=C2C=C(C(NC2=C(C=1)NC)=O)C(=O)NC=1C=NC=NC=1 WXHGTUVYWLEYAR-UHFFFAOYSA-N 0.000 description 1
- UMTBCDLZQQIIBT-UHFFFAOYSA-N 6-fluoro-8-(methylamino)-N-[4-(2-morpholin-4-ylethylcarbamoyl)phenyl]-2-oxo-1H-quinoline-3-carboxamide Chemical compound N1(CCOCC1)CCNC(=O)C1=CC=C(NC(=O)C2=CC3=CC(F)=CC(NC)=C3NC2=O)C=C1 UMTBCDLZQQIIBT-UHFFFAOYSA-N 0.000 description 1
- PVKSAUIBQPEFCD-UHFFFAOYSA-N 6-fluoro-8-(methylamino)-N-[4-(oxan-2-yloxycarbamoyl)phenyl]-2-oxo-1H-quinoline-3-carboxamide Chemical compound C1=CC(=CC=C1NC(=O)C1=CC2=CC(F)=CC(NC)=C2NC1=O)C(=O)NOC1CCCCO1 PVKSAUIBQPEFCD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XJHGOXQZDOLIKS-UHFFFAOYSA-N 8-(1-hydroxyethyl)-1H-quinolin-2-one Chemical compound OC(C)C=1C=CC=C2C=CC(NC=12)=O XJHGOXQZDOLIKS-UHFFFAOYSA-N 0.000 description 1
- IKCMZHMBBZCHAK-UHFFFAOYSA-N 8-(hydroxymethyl)-1H-quinolin-2-one Chemical compound OCC1=C2N=C(O)C=CC2=CC=C1 IKCMZHMBBZCHAK-UHFFFAOYSA-N 0.000 description 1
- CBGCVPJEHCTABH-UHFFFAOYSA-N 8-[benzyl(methyl)amino]-6-fluoro-4-hydroxy-2-oxo-N-[4-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]-1H-quinoline-3-carboxamide Chemical compound N1C(=O)ON=C1C1=CC=C(NC(=O)C2=C(C3=C(C(N(CC4=CC=CC=C4)C)=CC(F)=C3)NC2=O)O)C=C1 CBGCVPJEHCTABH-UHFFFAOYSA-N 0.000 description 1
- ZRGBVZKMGODGPX-UHFFFAOYSA-N 8-[benzyl(methyl)amino]-6-fluoro-4-hydroxy-N-[4-(methylsulfonylcarbamoyl)phenyl]-2-oxo-1H-quinoline-3-carboxamide Chemical compound S(=O)(=O)(C)NC(=O)C1=CC=C(NC(=O)C2=C(C3=CC(F)=CC(N(CC4=CC=CC=C4)C)=C3NC2=O)O)C=C1 ZRGBVZKMGODGPX-UHFFFAOYSA-N 0.000 description 1
- CQYXDBXNBMEORX-UHFFFAOYSA-N 8-[benzyl(methyl)amino]-N-(4-cyanophenyl)-6-fluoro-4-hydroxy-2-oxo-1H-quinoline-3-carboxamide Chemical compound C1=C(C=CC(=C1)NC(=O)C1=C(C2=C(C(=CC(F)=C2)N(CC2=CC=CC=C2)C)NC1=O)O)C#N CQYXDBXNBMEORX-UHFFFAOYSA-N 0.000 description 1
- OWJDLKGVHMTXSG-UHFFFAOYSA-N 8-ethenyl-1h-quinolin-2-one Chemical compound C1=CC=C(C=C)C2=NC(O)=CC=C21 OWJDLKGVHMTXSG-UHFFFAOYSA-N 0.000 description 1
- FOBANIGHCBBRFD-UHFFFAOYSA-N 8-nitro-2-oxo-1H-quinoline-3-carboxylic acid Chemical compound OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]c1=O FOBANIGHCBBRFD-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MGJVFMGVHWBKSV-UHFFFAOYSA-N CC(C)(C)N(CC1)CCN1C(N=C1)=NC=C1NC(C1=CC2=CC(F)=CC(NC)=C2NC1=O)=O Chemical compound CC(C)(C)N(CC1)CCN1C(N=C1)=NC=C1NC(C1=CC2=CC(F)=CC(NC)=C2NC1=O)=O MGJVFMGVHWBKSV-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)(C)OC(NC1(CC2)CCN2c(nc2)ncc2NC(C2=Cc3cccc(NC)c3NC2=O)=O)=*C1=O Chemical compound CC(C)(C)OC(NC1(CC2)CCN2c(nc2)ncc2NC(C2=Cc3cccc(NC)c3NC2=O)=O)=*C1=O 0.000 description 1
- YSECIGVJKBONCY-UHFFFAOYSA-N CC(C)(C)OC(Nc1c(N(C)Cc2ccccc2)nccc1C=O)=O Chemical compound CC(C)(C)OC(Nc1c(N(C)Cc2ccccc2)nccc1C=O)=O YSECIGVJKBONCY-UHFFFAOYSA-N 0.000 description 1
- RHRDNXWTTXFQGR-UHFFFAOYSA-N CC(C)(C)OC(Nc1nc(CNc(nc2)ncc2NC(C2=Cc(cccc3NC)c3NC2=O)=O)c[s]1)=O Chemical compound CC(C)(C)OC(Nc1nc(CNc(nc2)ncc2NC(C2=Cc(cccc3NC)c3NC2=O)=O)c[s]1)=O RHRDNXWTTXFQGR-UHFFFAOYSA-N 0.000 description 1
- JCXOSMCJGBTBDC-UHFFFAOYSA-N CC(C)(C)OC(c(cc1)ccc1NC(CC(Nc(c(C(CCN(C)C(OC(C)(C)C)=O)=O)cc(F)c1)c1N(C)Cc1ccccc1)=O)=O)=O Chemical compound CC(C)(C)OC(c(cc1)ccc1NC(CC(Nc(c(C(CCN(C)C(OC(C)(C)C)=O)=O)cc(F)c1)c1N(C)Cc1ccccc1)=O)=O)=O JCXOSMCJGBTBDC-UHFFFAOYSA-N 0.000 description 1
- BTEYOILJVIONOI-UHFFFAOYSA-N CC1CCN(CCN)CC1 Chemical compound CC1CCN(CCN)CC1 BTEYOILJVIONOI-UHFFFAOYSA-N 0.000 description 1
- UKRRFEVNKKDXDT-UHFFFAOYSA-N CCOC(CC(Nc(cc1)ccc1C(OC(C)(C)C)=O)=O)=O Chemical compound CCOC(CC(Nc(cc1)ccc1C(OC(C)(C)C)=O)=O)=O UKRRFEVNKKDXDT-UHFFFAOYSA-N 0.000 description 1
- LAEYJPYRJWFXAZ-UHFFFAOYSA-N CCOC(c(cc1)cc(CN2CCOCC2)c1NC(C(C(Nc(c1cc(F)c2)c2N(C)Cc2ccccc2)=O)=C1O)=O)=O Chemical compound CCOC(c(cc1)cc(CN2CCOCC2)c1NC(C(C(Nc(c1cc(F)c2)c2N(C)Cc2ccccc2)=O)=C1O)=O)=O LAEYJPYRJWFXAZ-UHFFFAOYSA-N 0.000 description 1
- JZRUQZMZAPUHAP-UHFFFAOYSA-N CCOC(c(cc1)ccc1NC(C(C(Nc(c1cc(F)c2)c2NC)=O)=C1O)=O)=O Chemical compound CCOC(c(cc1)ccc1NC(C(C(Nc(c1cc(F)c2)c2NC)=O)=C1O)=O)=O JZRUQZMZAPUHAP-UHFFFAOYSA-N 0.000 description 1
- OFPPRCUXTVMPJI-UHFFFAOYSA-N CNC1=C2C(=CC(=C1)F)C=CC(=O)N2C3=CC=C(C=C3)C(C(=O)N)O Chemical compound CNC1=C2C(=CC(=C1)F)C=CC(=O)N2C3=CC=C(C=C3)C(C(=O)N)O OFPPRCUXTVMPJI-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MRLVFVTVXSKAMX-UHFFFAOYSA-N Methyl 4-amino-3-iodobenzoate Chemical compound COC(=O)C1=CC=C(N)C(I)=C1 MRLVFVTVXSKAMX-UHFFFAOYSA-N 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- ZJHNDNOGDIGWNF-UHFFFAOYSA-N N-(2-amino-1,3-thiazol-5-yl)-8-(methylamino)-2-oxo-1H-quinoline-3-carboxamide hydrochloride Chemical compound Cl.NC=1SC(=CN=1)NC(=O)C=1C(NC2=C(C=CC=C2C=1)NC)=O ZJHNDNOGDIGWNF-UHFFFAOYSA-N 0.000 description 1
- KOEDPLURSTYMHA-UHFFFAOYSA-N N-[2-[[cyclohexyl(methyl)amino]methyl]phenyl]-8-(methylamino)-2-oxo-1H-quinoline-3-carboxamide Chemical compound C1CC(N(CC2=C(NC(=O)C3=CC4=CC=CC(NC)=C4NC3=O)C=CC=C2)C)CCC1 KOEDPLURSTYMHA-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- SZTNSCNBCNZMEI-UHFFFAOYSA-N N-[4-(2,4-dioxo-1,3-oxazolidin-5-yl)phenyl]-6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carboxamide Chemical compound O1C(=O)NC(=O)C1C1=CC=C(NC(=O)C2=CC3=CC(F)=CC(NC)=C3NC2=O)C=C1 SZTNSCNBCNZMEI-UHFFFAOYSA-N 0.000 description 1
- AIILIANMNYSHIZ-UHFFFAOYSA-N N-[4-[[tert-butyl(diphenyl)silyl]oxymethyl]pyridin-3-yl]-6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carboxamide Chemical compound C1=CC([Si](C(C)(C)C)(C2=CC=CC=C2)OCC2=C(NC(=O)C3=CC4=CC(F)=CC(NC)=C4NC3=O)C=NC=C2)=CC=C1 AIILIANMNYSHIZ-UHFFFAOYSA-N 0.000 description 1
- CXFJFHLYPIWRIK-UHFFFAOYSA-N N-benzyl-3-[1-[tert-butyl(dimethyl)silyl]oxybut-3-enyl]-5-fluoro-N-methyl-2-nitroaniline Chemical compound C(C1=CC=CC=C1)N(C1=C(C(=CC(=C1)F)C(CC=C)O[Si](C)(C)C(C)(C)C)[N+](=O)[O-])C CXFJFHLYPIWRIK-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- BNQZCLHKOKRYIM-UHFFFAOYSA-N [NH2-].[Na+].[NH2-].[Li+] Chemical compound [NH2-].[Na+].[NH2-].[Li+] BNQZCLHKOKRYIM-UHFFFAOYSA-N 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- YZJAYMFMAYLVIB-UHFFFAOYSA-N benzoic acid oxolane Chemical compound O1CCCC1.C(C1=CC=CC=C1)(=O)O YZJAYMFMAYLVIB-UHFFFAOYSA-N 0.000 description 1
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 1
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- KZIBQYUFIVUOHY-UHFFFAOYSA-N bis(2-methylpropyl)alumane toluene Chemical compound Cc1ccccc1.[H][Al](CC(C)C)CC(C)C KZIBQYUFIVUOHY-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- QHXLIQMGIGEHJP-UHFFFAOYSA-N boron;2-methylpyridine Chemical compound [B].CC1=CC=CC=N1 QHXLIQMGIGEHJP-UHFFFAOYSA-N 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 description 1
- 229960000400 butamben Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- CSTBBLHIGMTEAZ-UHFFFAOYSA-N chloroform;ethyl acetate;hexane Chemical compound ClC(Cl)Cl.CCCCCC.CCOC(C)=O CSTBBLHIGMTEAZ-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- WTIJXIZOODAMJT-DHFGXMAYSA-N coumermycin A1 Chemical compound O([C@@H]1[C@H](C(O[C@@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C(=C(C(=O)NC=5C(OC6=C(C)C(O[C@H]7[C@@H]([C@H](OC(=O)C=8NC(C)=CC=8)[C@@H](OC)C(C)(C)O7)O)=CC=C6C=5O)=O)NC=4)C)=C(O)C3=CC=2)C)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 WTIJXIZOODAMJT-DHFGXMAYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- RSSPNKIJFWFVRV-UHFFFAOYSA-N diazomethyl(trimethyl)silane;ethoxyethane Chemical compound CCOCC.C[Si](C)(C)C=[N+]=[N-] RSSPNKIJFWFVRV-UHFFFAOYSA-N 0.000 description 1
- DBKKFIIYQGGHJO-UHFFFAOYSA-N diethyl 2-oxopropanedioate Chemical compound CCOC(=O)C(=O)C(=O)OCC DBKKFIIYQGGHJO-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- UESSEMPSSAXQJC-UHFFFAOYSA-N ethanol;methanamine Chemical compound NC.CCO UESSEMPSSAXQJC-UHFFFAOYSA-N 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- QDGMMKGDODELDC-UHFFFAOYSA-N ethyl 2-oxo-1h-1,6-naphthyridine-3-carboxylate Chemical compound N1=CC=C2NC(=O)C(C(=O)OCC)=CC2=C1 QDGMMKGDODELDC-UHFFFAOYSA-N 0.000 description 1
- KWFADUNOPOSMIJ-UHFFFAOYSA-N ethyl 3-chloro-3-oxopropanoate Chemical compound CCOC(=O)CC(Cl)=O KWFADUNOPOSMIJ-UHFFFAOYSA-N 0.000 description 1
- FMDOQNLSMCBRJE-UHFFFAOYSA-N ethyl 6-fluoro-8-(methylamino)-2-oxo-1H-quinoline-3-carboxylate Chemical compound C1=C(C(=O)NC2=C1C=C(F)C=C2NC)C(=O)OCC FMDOQNLSMCBRJE-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- RDNFXAWOOHTXBF-UHFFFAOYSA-N methyl 3,5-difluoro-2-nitrobenzoate Chemical compound COC(=O)C1=CC(F)=CC(F)=C1[N+]([O-])=O RDNFXAWOOHTXBF-UHFFFAOYSA-N 0.000 description 1
- XHHHBBWBUGFEBX-UHFFFAOYSA-N methyl 4-amino-3-[[cyclohexyl(methyl)amino]methyl]benzoate Chemical compound NC1=C(C=C(C(=O)OC)C=C1)CN(C)C1CCCCC1 XHHHBBWBUGFEBX-UHFFFAOYSA-N 0.000 description 1
- DWOYOOQZMOHWPA-UHFFFAOYSA-N methyl 4-amino-3-[[cyclohexyl(methyl)amino]methyl]benzoate hydrochloride Chemical compound Cl.NC1=C(C=C(C(=O)OC)C=C1)CN(C)C1CCCCC1 DWOYOOQZMOHWPA-UHFFFAOYSA-N 0.000 description 1
- KMHKZPYJAASHGP-UHFFFAOYSA-N methyl 4-amino-3-ethenylbenzoate Chemical compound COC(=O)C1=CC=C(N)C(C=C)=C1 KMHKZPYJAASHGP-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-M novobiocin(1-) Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-M 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000005961 oxazepanyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QGLVEAGMVUQOJP-UHFFFAOYSA-N prop-2-enylboronic acid Chemical compound OB(O)CC=C QGLVEAGMVUQOJP-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 1
- ZFCHNZDUMIOWFV-UHFFFAOYSA-M pyrimidine-2-carboxylate Chemical compound [O-]C(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-M 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001023 sodium amalgam Inorganic materials 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 1
- ZOFJBHYCGASUQK-UHFFFAOYSA-N sodium;trimethylsilylazanide Chemical compound [Na+].C[Si](C)(C)[NH-] ZOFJBHYCGASUQK-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- MEPSWGJJMNJKQN-UHFFFAOYSA-N tert-butyl 3-amino-3-oxopropanoate Chemical compound CC(C)(C)OC(=O)CC(N)=O MEPSWGJJMNJKQN-UHFFFAOYSA-N 0.000 description 1
- UOFXCDLVMBOPFE-UHFFFAOYSA-N tert-butyl 4-(5-aminopyrimidin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=NC=C(N)C=N1 UOFXCDLVMBOPFE-UHFFFAOYSA-N 0.000 description 1
- DVCCYSPYGJYHOC-UHFFFAOYSA-N tert-butyl 4-amino-3-[cyclohexyl(methyl)amino]benzoate Chemical compound NC1=C(C=C(C(=O)OC(C)(C)C)C=C1)N(C)C1CCCCC1 DVCCYSPYGJYHOC-UHFFFAOYSA-N 0.000 description 1
- KYORUZMJUKHKFS-UHFFFAOYSA-N tert-butyl 4-aminobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(N)C=C1 KYORUZMJUKHKFS-UHFFFAOYSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000004587 thienothienyl group Chemical group S1C(=CC2=C1C=CS2)* 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- XTTGYFREQJCEML-UHFFFAOYSA-N tributyl phosphite Chemical compound CCCCOP(OCCCC)OCCCC XTTGYFREQJCEML-UHFFFAOYSA-N 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FICPQAZLPKLOLH-UHFFFAOYSA-N tricyclohexyl phosphite Chemical compound C1CCCCC1OP(OC1CCCCC1)OC1CCCCC1 FICPQAZLPKLOLH-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- WXAZIUYTQHYBFW-UHFFFAOYSA-N tris(4-methylphenyl)phosphane Chemical compound C1=CC(C)=CC=C1P(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 WXAZIUYTQHYBFW-UHFFFAOYSA-N 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Abstract
Description
(1)式[1]
Zは、NH-R1、C1-4アルキル基(該C1-4アルキル基は、アミノ基又はヒドロキシ基で置換されてもよい。)又はヒドロキシ基を示し、
R1は、水素原子又はC1-4アルキル基を示し、
T、U、V及びWは、全てがC-R2又はどれか1つがNでそれ以外はC-R2を示し、
各R2は、独立的に、水素原子、ハロゲン原子、ヒドロキシ基、C1-6アルキル基、C1-6アルコキシ基(該C1-6アルキル基及び該C1-6アルコキシ基は、-N(R21)(R22)で置換されてもよい。)又はアミノ基[該アミノ基は、C1-6アルキル基(該C1-6アルキル基は、ピペリジン-4-イル基、ピロリジン-3-イル基、アゼチジン-3-イル基、1-アミノ-シクロブタン-3-イル基、モルホリニル基又は-N(R23)(R24)で置換されてもよい。)、1-アミノ-シクロブタン-3-イル基又は式[2]に記載の置換基のいずれかで置換されてもよい。]を示し、
L1は、-CONR3-、-COO-、-(CH2)nNR3-又は-NR3CO-を示し、
R3は、水素原子又はC1-6アルキル基を示し、
nは1から4の整数を示し、
L2は、結合手、C1-6アルキレン基、ピペリジンジイル基、ピロリジンジイル基及びアゼチジンジイル基(該C1-6アルキレン基、該ピペリジンジイル基、該ピロリジンジイル基及び該アゼチジンジイル基は、カルボキシ基又はオキソ基で置換されてもよい。)からなる群から選ばれる基を示し、
Aは、アリール基、ヘテロ環基又はC3-8シクロアルキル基(該アリール基、該ヘテロ環基及び該C3-8シクロアルキル基は、下記の置換基群Raより同一に又は異なって選ばれる1個から4個の置換基で置換されてもよい。)を示し、
置換基群Raは、C1-6アルキル基(該C1-6アルキル基は、カルボキシ基、ヒドロキシ基、C3-8シクロアルキル基、カルバモイル基及び-N(R11)(R12)からなる群から選ばれる1個から2個の置換基で置換されてもよい。)、カルボキシ基、ヒドロキシ基、ヘテロ環基、アミジノ基、-N(R13)(R14)、-CON(R15)(R16)、C1-6アルコキシ基(該C1-6アルコキシ基は、アミノ基、N-メチルピペラジニル基及びモルホリニル基から選ばれる1個から2個の置換基で置換されてもよい。)、C2-6アルケニル基(該C2-6アルケニル基は、ヒドロキシ基又は-N(R17)(R18)で置換されてもよい。)、-COOR19、3-アミノアゼチジニル基、ピペラジニル基(該ピペラジニル基は、1個のメチル基で置換されてもよい。)、4-アミノピペリジニル基又は式[3]に記載の置換基のいずれかを示し、
R11及びR12は、結合する窒素原子と一緒になって、飽和の3員環から7員環を形成してもよく、ここで、該飽和の3員環から7員環は、環内にさらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよく、また、該飽和の3員環から7員環は、アミノ基で置換されてもよく、
R13及びR14は、同一に又は異なって水素原子、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、-CONHSO2Me、C1-6アルキル基[該C1-6アルキル基は、アミノ基、N-メチルピペラジニル基、モルホリニル基、-N(CH2CH2OH)2及びヘテロ環基(該ヘテロ環基は、アミノ基で置換されてもよい。)から選ばれる1個から2個の置換基で置換されてもよい。]を示し、
R15及びR16は、同一に又は異なって水素原子、ヒドロキシ基、1,3-ジヒドロキシプロパン-2-イル基、メタンスルホニル基、N,N-ジメチルスルファモイル基及びC1-6アルキル基(該C1-6アルキル基は、アミノ基、モルホリニル基、ピペリジニル基、カルボキシ基、ヒドロキシ基及び式[4]に記載の置換基からなる群より同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)を示すか、又は、
R17及びR18は、同一に又は異なって水素原子又はC1-6アルキル基を示し、
R19は、C1-6アルキル基を示し、
R20は、水素原子又はC1-6アルキル基を示す。}
で表される化合物又はその薬学的に許容される塩、
(2)ZがNH-R1、C1-4アルキル基又はヒドロキシ基であり、R1がC1-4アルキル基である、(1)に記載の化合物又はその薬学的に許容される塩、
(3)ZがNH-R1、エチル基又はヒドロキシ基であり、R1がメチル基である、(2)に記載の化合物又はその薬学的に許容される塩、
(4)ZがNH-R1であり、R1がメチル基である、(3)に記載の化合物又はその薬学的に許容される塩、
(5)T、U、V及びWがC-R2である、(4)に記載の化合物又はその薬学的に許容される塩、
(6)L1が-CONR3-、-COO-又は-(CH2)nNR3-である、(5)に記載の化合物又はその薬学的に許容される塩、
(7)L1が-CONR3-である、(6)に記載の化合物又はその薬学的に許容される塩、
(8)R3が水素原子である、(7)に記載の化合物又はその薬学的に許容される塩、
(9)L2が結合手、メチレン基又はエチレン基、ピペリジンジイル基、ピロリジンジイル基、アゼチジンジイル基からなる群から選ばれる結合手又は基である、(8)に記載の化合物又はその薬学的に許容される塩、
(10)L2が結合手又はエチレン基である、(9)に記載の化合物又はその薬学的に許容される塩、
(11)L2が結合手である、(10)に記載の化合物又はその薬学的に許容される塩、
(12)T、U、V及びWがC-R2であり、各R2が、独立的に、水素原子、ハロゲン原子、ヒドロキシ基、C1-6アルキル基(該C1-6アルキル基は、-N(R21)(R22)で置換されてもよい。)、C1-6アルコキシ基又はアミノ基[該アミノ基は、C1-6アルキル基(該C1-6アルキル基は、ピペリジン-4-イル基、ピロリジン-3-イル基、アゼチジン-3-イル基、1-アミノ-シクロブタン-3-イル基、モルホリノ基又は-N(R23)(R24)で置換されてもよい。)、1-アミノ-シクロブタン-3-イル基又は式[2]に記載の置換基のいずれかで置換されてもよい。]であり、
(13)R2が、水素原子、フッ素原子、ヒドロキシ基、エチル基、n-プロピル基(該エチル基及び該n-プロピル基は、-N(R21)(R22)で置換されてもよい。)、C1-6アルコキシ基、アミノ基[該アミノ基は、メチル基、エチル基、n-プロピル基(該メチル基、該エチル基及び該n-プロピル基は、ピペリジン-4-イル基、ピロリジン-3-イル基、アゼチジン-3-イル基、1-アミノ-シクロブタン-3-イル基、モルホリノ基及び-N(R23)(R24)からなる群から選ばれる1個から2個の置換基で置換されてもよい。)、1-アミノ-シクロブタン-3-イル基又は式[2]に記載の置換基のいずれかで置換されてもよい。]であり、
(14)各R2が、独立的に、水素原子、フッ素原子又はヒドロキシ基である、(13)に記載の化合物又はその薬学的に許容される塩、
(15)UがC-F又はC-Hであり、T及びVがC-Hであり、WがC-R2である(13)に記載の化合物又はその薬学的に許容される塩、
(16)Aが、アリール基又はヘテロ環基(該アリール基及び該ヘテロ環基は、置換基群Raより同一に又は異なって選ばれる1から4個の置換基で置換されてもよい。)である、(1)から(15)のいずれか1項に記載の化合物又はその薬学的に許容される塩、
(17)Aが、アリール基又はヘテロ環基(該アリール基及び該ヘテロ環基は、置換基群Rbより同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)であり、
Rbは、C1-6アルキル基(該C1-6アルキル基は、カルボキシ基、ヒドロキシ基、カルバモイル基及び-N(R11)(R12)からなる群より同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)、カルボキシ基、ヒドロキシ基、ヘテロ環基、アミジノ基、-N(R13)(R14)、-CON(R15)(R16)、C1-6アルコキシ基(該C1-6アルコキシ基は、アミノ基、N-メチルピペラジニル基又はモルホリノ基で置換されてもよい。)、C2-6アルケニル基(該C2-6アルケニル基は、ヒドロキシ基又は-N(R17)(R18)で置換されてもよい。)、3-アミノアゼチジノ基、ピペラジニル基(該ピペラジニル基は、1個のメチル基で置換されてもよい。)、4-アミノピペリジノ基又は式[3]に記載の置換基のいずれかであり、
R11及びR12が結合する窒素原子と一緒になって、形成する飽和の3員環から7員環は、アゼチジニル基、ピロリジニル基、ピペリジニル基又はモルホリノ基であり、
R13及びR14は、同一に又は異なって水素原子、t-ブトキシカルボニル基、シクロヘキシル基、-CONHSO2Me、メチル基、エチル基又はn-プロピル基(該メチル基、該エチル基及び該n-プロピル基は、アミノ基、N-メチルピペラジノ基、モルホリニル基、-N(CH2CH2OH)2及びヘテロ環基からなる群から選ばれる1個から2個の置換基で置換されてもよい。)であり、
R15及びR16は、同一に又は異なって水素原子、ヒドロキシ基、1,3-ジヒドロキシプロパン-2-イル基、メタンスルホニル基、N,N-ジメチルスルファモイル基及びC1-6アルキル基(該C1-6アルキル基は、アミノ基、モルホリニル基、ピペリジニル基、カルボキシ基、ヒドロキシ基及び式[4]に記載の置換基からなる群より同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)であるか、又は
R17及びR18は、同一に又は異なって水素原子又はメチル基であり、
R20は、水素原子又はメチル基である、(16)に記載の化合物又はその薬学的に許容される塩、
(18)Aが、フェニル基又はヘテロ環基(該フェニル基及び該ヘテロ環基は、下記の置換基群Rcより同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)であり、
Rcは、メチル基(該メチル基は、カルボキシ基、ヒドロキシ基、カルバモイル基及び-N(R11)(R12)からなる群より同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)、カルボキシ基及びヘテロ環基及び-CON(R15)(R16)であり、
R11及びR12は、同一に又は異なって水素原子、メチル基、n-ペンチル基、n-オクチル基、シクロプロピル基、シクロヘキシル基、ヒドロキシエチル基、N-メチルピペリジン-4-イル基、カルボキシメチル基、N,N-ジメチルアミノプロピル基及びアミノエチル基からなる群から選ばれる原子又は基であるか、又は
R11及びR12が結合する窒素原子と一緒になって形成する飽和の3員環から7員環は、アゼチジニル基、ピロリジニル基、ピペリジニル基又はモルホリノ基であり、
R15及びR16は、同一に又は異なって水素原子、メタンスルホニル基、N,N-ジメチルスルファモイル基、メチル基、エチル基又はn-プロピル基(該メチル基、エチル基又はn-プロピル基は、アミノ基、モルホリニル基、ピペリジニル基及びヒドロキシ基からなる群から選ばれる1個から2個の置換基で置換されてもよい。)である、(17)に記載の化合物又はその薬学的に許容される塩、
(19)(1)から(18)の化合物又はその薬学的に許容される塩を含有する医薬組成物、
(20)(1)から(18)の化合物又はその薬学的に許容される塩を含有するGyrB/ParE阻害剤、
(21)(1)から(18)の化合物又はその薬学的に許容される塩を含有する抗菌剤、である。
「C3-8シクロアルキル基」とは、炭素原子数3から8個のシクロアルキル基であり、例えば、c-プロピル基、c-ブチル基、c-ペンチル基、c-ヘキシル基、c-ヘプチル基及びc-オクチル基が挙げられる。
2-アミノアジリジニル基、3-アミノアゼチジニル基、2-アミノピロリジニル基、3-アミノピロリジニル基、2-アミノピペリジニル基、3-アミノピペリジニル基、4-アミノピペリジニル基、2-アミノアゼパ二ル基、3-アミノアゼパ二ル基及び4-アミノアゼパ二ル基などが挙げられる。
最も好ましいT、U、V、WはC-R2であり、ここでR2は、水素原子、フッ素原子、ヒドロキシ基である。さらに好ましくは、UがC-F又はC-Hであり、T及びVがC-Hであり、WがC-R2(R2の好ましい例は上記の通り)である。
R3は、水素原子又はメチル基であり、nは1である。より好ましいL1は、-CONR3-であり、R3は、水素原子である。
Rbは、C1-6アルキル基(該C1-6アルキル基は、「カルボキシ基、ヒドロキシ基、カルバモイル基、-N(R11)(R12)」より選ばれる1から2個の置換基で置換されてもよい。)、カルボキシ基、ヒドロキシ基、ヘテロ環基、アミジノ基、-N(R13)(R14)、-CON(R15)(R16)、C1-6アルコキシ基(該C1-6アルコキシ基は、アミノ基、N-メチルピペラジニル基、モルホリノ基で置換されてもよい。)、C2-6アルケニル基(該C2-6アルケニル基は、ヒドロキシ基、-N(R17)(R18)で置換されてもよい。)、3-アミノアゼチジノ基、ピペラジニル基、N-メチルピペラジニル基、 4-アミノピペリジノ基、または式[3]に記載の置換基であり、
R11及びR12は、結合する窒素原子と一緒になって、アゼチジニル基、ピロリジニル基、ピペリジニル基、モルホリニル基であり、
R13及びR14は、同一又は異なって水素原子、t-ブトキシカルボニル基、シクロヘキシル基、-CONHSO2Me、メチル基、エチル基及びn-プロピル基(該メチル基、エチル基及びn-プロピル基は、アミノ基、N-メチルピペラジニル基、モルホリノ基、-N(CH2CH2OH)2、ヘテロ環基で置換されても良い)であり、
R15及びR16は、同一又は異なって水素原子、ヒドロキシ基、1,3-ジヒドロキシプロパン-2-イル基、メタンスルホニル基、N,N-ジメチルスルファモイル基、C1-6アルキル基(該C1-6アルキル基は、「アミノ基、モルホリノ基、ピペリジノ基、ピペリジン-4-イル基、カルボキシ基、ヒドロキシ基、式[4]に記載の置換基」より選ばれる1から2個の置換基で置換されてもよい)であるか、又は
Rcは、メチル基(該メチル基は、「カルボキシ基、ヒドロキシ基、カルバモイル基、-N(R11)(R12)」より選ばれる1から2個の置換基で置換されてもよい。)、
カルボキシ基、ヘテロ環基、-CON(R15)(R16)、
R11及びR12は、同一または異なって水素原子、メチル基、n-ペンチル基、n-オクチル基、シクロプロピル基、シクロヘキシル基、ヒドロキシエチル基、N-メチルピペリジン-4-イル基、カルボキシメチル基、N,N-ジメチルアミノプロピル基、アミノエチル基であるか、又は、
R11及びR12は、結合する窒素原子と一緒になって、アゼチジニル基、ピロリジニル基、ピペリジニル基、モルホリニル基であり、
R15及びR16は、同一又は異なって水素原子、メタンスルホニル基、N,N-ジメチルスルファモイル基、メチル基、エチル基又はn-プロピル基(該メチル基、エチル基又はn-プロピル基は、「アミノ基、モルホリノ基、ピペリジノ基、ピペリジン-4-イル基、ヒドロキシ基」で置換されてもよい)である。
「シリカゲル 60 N」には関東化学社製シリカゲル 60N、「クロマトレックスNH」には富士シリシア化学社製クロマトレックス(登録商標)NHをそれぞれ市販されているものを使用した。TLCを使用して精製した際のTLC(シリカゲルプレート)にはSilica gel 60F254(メルク)、TLC(NHシリカゲルプレート)にはTLCプレートNH(Fuji Silysia)を使用した。Phase separatorはbiotage株式会社製のものを用いた。
YMC-Actus Triart C18,5.0μm,φ30×50mm
Xbridge Prep C18,5.0μm OBD,φ30×50mm
Waters XSlect CSH C18,5.0μm,φ30×50mm
分取装置:Agilent社 Agilent 1260Infinity及びAgilent 6130(イオン化法:Electron Spray Ionization:ESI)、ELSD検出器が付属する場合は Agilent 385-ELSDを用いた。
溶媒:A液;0.1%ギ酸含有水、B液;0.1%ギ酸含有アセトニトリル
流速:50mL/min
0.0-0.5 min(A液/B液 = 90/10)
0.5-7.5 min(A液/B液 = 90/10~20/80)
7.5-7.95 min(A液/B液 = 20/80)
7.95-8.0 min(A液/B液 = 20/80~5/95)
8.0-9.0 min(A液/B液 = 5/95)
流速:50mL/min
0.0-0.5 min(A液/B液 = 95/5)
0.5-7.5 min(A液/B液 = 95/5~50/50)
7.5-7.95 min(A液/B液 = 50/50)
7.95-8.0 min(A液/B液 = 50/50~5/95)
8.0-9.0 min(A液/B液 = 5/95)
流速:50mL/min
0.0-0.5 min(A液/B液 = 80/20)
0.5-7.0 min(A液/B液 = 80/20~5/95)
7.0-7.45 min(A液/B液 = 5/95)
7.45-7.5 min(A液/B液 = 5/95~1/99)
7.5-9.0 min(A液/B液 = 1/99)
流速:40mL/min
0.0-2.0 min(A液/B液 = 90/10)
2.0-11.0 min(A液/B液 = 90/10~20/80)
11.0 -12.0 min(A液/B液 = 20/80~5/95)
12.0-13.5 min(A液/B液 = 5/95)
マイクロウェーブ反応装置:Initiator(Biotage AB)
NMRスペクトル:[1H-NMR]600MHz:JNM-ECA600(日本電子)、500MHz:JNM-ECA500(日本電子)、400MHz:AVANCE III HD 400(BRUKER)
測定機器:Shimadzu社 LCMS-2010EV
カラム:Shimadzu XR-ODS,2.2μm,φ2.0×30mm
イオン化法:ESI/APCI(atmospheric pressure chemical ionization)dual source
溶媒:A液;0.1%ギ酸含有水、B液;0.1%ギ酸含有アセトニトリル
流速:0.6mL/min、検出法:254nm
グラジエント:
0.0-0.5 min(A液/B液 = 90/10)
0.5-1.5 min(A液/B液 = 90/10~60/40)
1.5-2.5 min(A液/B液 = 60/40~1/99)
2.5-5.0 min(A液/B液 = 1/99)
測定機器:Agilent社 Agilent 1290Infinity及びAgilent 6130又は6150、ELSD検出器が付属する場合はAgilent 385-ELSDを用いた。
カラム:Waters社 Acquity CSH C18,1.7μm,φ2.1×50mm
イオン化法:ESI
溶媒:A液;0.1%ギ酸含有水、B液;0.1%ギ酸含有アセトニトリル
流速:0.8mL/min、検出法:254nm
グラジエント:
0.0-0.8 min(A液/B液 = 95/5~60/40)
0.8-1.08 min(A液/B液 = 60/40~1/99)
1.08-1.38 min(A液/B液 =1/99)
測定機器、カラム、イオン化法、溶媒、流速、検出法は分析条件2と同じ。
グラジエント:
0.0-1.2 min(A液/B液 = 80/20~1/99)
1.2-1.4 min(A液/B液 =1/99)
測定機器、カラム、イオン化法、溶媒、流速、検出法は分析条件2と同じ。
グラジエント:
0.0-0.8 min(A液/B液 = 70/30~1/99)
0.8-1.4 min(A液/B液 =1/99)
AcOEt:酢酸エチル
APCI:大気圧化学イオン化法
aq.:水溶液
Boc:t-ブトキシカルボニル
Bn:ベンジル
Bu:ブチル
DEAD:アゾジカルボン酸ジエチル
DIPEA:N,N-ジイソプロピルエチルアミン
DMF:N,N-ジメチルホルムアミド
DMSO-d6:6重水素化ジメチルスルホキシド
ESI:エレクトロスプレーイオン化法
Et:エチル
HATU:O-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウムヘキサフルオロホスファート
HOBt・H2O:1-ヒドロキシベンゾトリアゾール一水和物
IBX:2-ヨードキシ安息香酸
IPA:イソプロピルアルコール
IPE:ジイソプロピルエーテル
LC:液体クロマトグラフィー
LDA:リチウムジイソプロピルアミド
Me:メチル
NMP:1-メチル-2-ピロリドン
PEPPSI:(1,3-ビス(2,6-ジイソプロピルフェニル)イミダゾリデン)(3-クロロピリジル)パラジウム(II)ジクロリド
PdCl2(dppf)・CH2Cl2:1,1’-ビス(ジフェニルホスフィノ)フェロセンパラジウム(II)クロリド ジクロロメタン錯体
PdCl2(PPh3)2:ビス(トリフェニルホスフィン)パラジウム(II)ジクロリド
PPTS:ピリジン 4-メチルベンゼンスルホナート
(p-Tol)3P:トリ(4-メチルフェニル)ホスフィン
p-TsOH・H2O:p-トルエンスルホン酸一水和物
TBAF:テトラ-n-ブチルアンモニウムフルオリド
TEA:トリエチルアミン
TFA:トリフルオロ酢酸
THF:テトラヒドロフラン
THP:テトラヒドロピラニル
TMS:トリメチルシリル
TIPS:トリイソプロピルシリル
TsCl;4-メチルベンゼンスルホニルクロリド
WSC・HCl:1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩
s:シングレット
br s:ブロードシングレット(幅広いシングレット)
d:ダブレット
br d:ブロードダブレット(幅広いダブレット)
dd:ダブルダブレット
dt:ダブルトリプレット
m:マルチプレット
t:トリプレット
br t:ブロードトリプレット(幅広いトリプレット)
td:トリプルダブレット
tt:トリプルトリプレット
q:カルテット
quin:クインテット
J:カップリング定数
Hz:ヘルツ
MS (ESI pos.) m/z : 247 [M+H]+,RT=0.782 min(分析条件3)
MS (ESI pos.) m/z : 219 [M+H]+,RT=0.693 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.86 (d, J=4.5 Hz, 3 H), 6.15 (br d, J=4.5 Hz, 1 H), 6.87 (br d, J=5.8 Hz, 1 H), 7.22 - 7.30 (m, 2 H), 8.87 (s, 1 H), 12.26 (br s, 1 H), 14.83 (br s, 1 H)
MS (ESI pos.) m/z : 201 [M+H]+,RT=0.709 min(分析条件3)
MS (ESI pos.) m/z : 199 [M+H]+,RT=0.817 min(分析条件3)
MS (ESI pos.) m/z : 169 [M+H]+,RT=0.757 min(分析条件3)
MS (ESI pos.) m/z : 265 [M+H]+,RT=0.864 min(分析条件3)
MS (ESI pos.) m/z : 237 [M+H]+,RT=0.758 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.85 (d, J=5.0 Hz, 3 H), 6.28 - 6.43 (m, 2 H), 6.76 (br s, 1 H), 8.47 (br s, 1 H)
MS (ESI pos.) m/z : 314 [M+H]+,RT=1.131 min(分析条件3)
MS (ESI pos.) m/z : 342 [M+H]+,RT=1.180 min(分析条件3)
MS (ESI pos.) m/z : 242 [M+H]+,RT=0.932 min(分析条件3)
MS (ESI pos.) m/z : 338 [M+H]+,RT=0.870 min(分析条件3)
MS (ESI pos.) m/z : 248 [M+H]+,RT=0.639 min(分析条件2)
MS (ESI pos.) m/z : 220 [M+H]+,RT=0.600 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 3.05 (br s, 3 H), 7.03 - 7.20 (m, 2 H), 7.28 - 7.52 (m, 1 H), 8.54 (s, 1 H), 12.61 (br s, 1 H)
MS (ESI pos.) m/z : 345 [M+H]+,RT=0.607 min(分析条件3)
MS (ESI pos.) m/z : 465 [M+H]+,RT=1.281 min(分析条件3)
MS (ESI pos.) m/z : 468 [M+H]+,RT=1.167 min(分析条件3)
MS (ESI pos.) m/z : 440 [M+H]+,RT=0.951 min(分析条件3)
MS (ESI pos.) m/z : 276 [M+H]+,RT=1.135 min(分析条件3)
MS (ESI pos.) m/z : 246 [M+H]+,RT=0.693 min(分析条件3)
MS (ESI pos.) m/z : 356 [M+H]+,RT=1.059 min(分析条件3)
MS (ESI pos.) m/z : 268 [M+H]+,RT=0.719 min(分析条件3)
MS (ESI pos.) m/z : 266 [M+H]+,RT=0.896 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.86 (s, 3 H), 6.33 (br s, 1 H), 6.58 (dd, J=11.7, 2.3 Hz, 1 H), 6.86 (dd, J=9.2, 2.3 Hz, 1 H)
MS (ESI pos.) m/z : 319 [M+H]+,RT=0.934 min(分析条件4)
MS (ESI pos.) m/z : 289 [M+H]+,RT=0.997 min(分析条件4)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 2.56 (s, 3 H), 3.87 (s, 3 H), 3.99 (s, 2 H), 6.13 (br s, 2 H), 6.89 (dd, J=9.5, 2.9 Hz, 1 H), 7.22 - 7.39 (m, 6 H)
MS (ESI pos.) m/z : 308 [M+H]+,RT=1.043 min(分析条件3)
MS (ESI neg.) m/z : 278 [M-H]-,RT=0.882 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 1.53 (s, 9 H), 3.35 - 3.39 (m, 2 H), 7.68 (d, J=8.7 Hz, 2 H), 7.86 (d, J=8.7 Hz, 2 H), 10.52 (br s, 1 H), 12.64 (br s, 1 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.55 (s, 9 H), 3.79 (s, 3 H), 3.83 (s, 3 H), 4.29 (d, J=5.9 Hz, 2 H), 4.43 (br t, J=5.9 Hz, 1 H), 6.42 (dd, J=8.3, 2.3 Hz, 1 H), 6.47 (d, J=2.3 Hz, 1 H), 6.57 (d, J=8.8 Hz, 2 H), 7.15 (d, J=8.3 Hz, 1 H), 7.79 (d, J=8.8 Hz, 2 H)
MS (ESI pos.) m/z : 458 [M+H]+,RT=0.920 min(分析条件4)
MS (ESI pos.) m/z : 430 [M+H]+,RT=0.809 min(分析条件4)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.59 (s, 9 H), 3.04 (s, 2 H), 3.55 (s, 3 H), 3.78 (s, 3 H), 4.94 (s, 2 H), 6.33 (d, J=2.3 Hz, 1 H), 6.39 (dd, J=8.3, 2.3 Hz, 1 H), 6.99 (d, J=8.4 Hz, 2 H), 7.08 (d, J=8.3 Hz, 1 H), 7.96 (d, J=8.4 Hz, 2 H)
MS (ESI pos.) m/z : 385 [M+H]+,RT=1.352 min(分析条件3)
MS (ESI pos.) m/z : 343 [M+H]+,RT=1.161 min(分析条件3)
MS (ESI pos.) m/z : 341 [M+H]+,RT=1.304 min(分析条件3)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 3.04 (d, J=5.3 Hz, 3 H), 3.83 (s, 3 H), 5.52 (s, 2 H), 5.84 (br s, 1 H), 6.47 (dd, J=11.1, 2.6 Hz, 1 H), 6.72 (dd, J=8.9, 2.6 Hz, 1 H), 6.94 (d, J=8.7 Hz, 2 H), 7.44 (d, J=8.7 Hz, 2 H), 8.47 (s, 1 H), 10.48 (s, 1 H)
MS (ESI pos.) m/z : 442 [M+Na]+,RT=0.863 min(分析条件4)
MS (ESI pos.) m/z : 364 [M+H]+,RT=0.617 min(分析条件4)
1H NMR (400 MHz, DMSO-d6) δ ppm 3.51 (s, 2 H), 3.85 (s, 3 H), 7.86 (d, J=8.5 Hz, 1 H), 7.95 (dd, J=8.5, 2.0 Hz, 1 H), 8.38 (d, J=2.0 Hz, 1 H), 9.79 (s, 1 H), 12.8 (br s, 1 H)
MS (ESI pos.) m/z : 241 [M+H]+,RT=0.873 min(分析条件3)
先の粗生成物のクロロホルム(100 mL)溶液に、二酸化マンガン(16 g)を加え50℃にて25時間攪拌した。反応終了後、反応混合物をセライトろ過し、そのろ液を減圧濃縮することにより、アルデヒド体の粗生成物を得た。得られた粗生成物は精製なしで次の反応に用いた。
MS (ESI pos.) m/z : 331 [M+H]+,RT=0.940 min(分析条件4)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm -0.12 (s, 3 H), 0.03 (s, 3 H), 0.87 (s, 9 H), 2.28 - 2.48 (m, 2 H), 2.66 (s, 3 H), 4.15 (s, 2 H), 4.67 (dd, J=7.3, 3.6 Hz, 1 H), 4.97 - 5.11 (m, 2 H), 5.70 - 5.87 (m, 1 H), 6.72 (dd, J=9.0, 2.6 Hz, 1 H), 6.96 (dd, J=9.0, 2.6 Hz, 1 H), 7.21 - 7.38 (m, 5 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm -0.15 (s, 3 H), 0.04 (s, 3 H), 0.89 (s, 9 H), 1.44 (s, 9 H), 1.70 - 2.00 (m, 2 H), 2.67 (s, 3 H), 2.82 (s, 3 H), 3.06 - 3.51 (m, 2 H), 4.16 (s, 2 H), 4.61 (br dd, J=8.3, 2.6 Hz, 1 H), 6.65 - 6.79 (m, 1 H), 6.95 (dd, J=8.3, 2.6 Hz, 1 H), 7.18 - 7.38 (m, 5 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm -0.15 (s, 3 H), 0.05 (s, 3 H), 0.88 (s, 9 H), 1.43 (s, 9 H), 1.92 - 2.06 (m, 1 H), 2.13 - 2.27 (m, 1 H), 2.55 (s, 3 H), 2.81 (s, 3 H), 2.97 - 3.43 (m, 2 H), 3.87 - 4.05 (m, 2 H), 4.51 - 4.64 (m, 3 H), 6.52 (br d, J=7.9 Hz, 1 H), 6.68 (dd, J=10.1, 2.3 Hz, 1 H), 7.20 - 7.35 (m, 5 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm -0.13 (s, 3 H), 0.04 (s, 3 H), 0.88 (s, 9 H), 1.50 - 1.84 (m, 4 H), 2.66 (s, 3 H), 3.58 - 3.68 (m, 2 H), 4.15 (s, 2 H), 4.61 - 4.70 (m, 1 H), 6.72 (dd, J=9.0, 2.7 Hz, 1 H), 6.96 (dd, J=9.0, 2.7 Hz, 1 H), 7.17 - 7.37 (m, 5 H)
MS (ESI pos.) m/z : 461 [M+H]+,RT=1.154 min(分析条件4)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm -0.14 (s, 3 H), 0.03 (s, 3 H), 0.88 (s, 9 H), 1.43 (s, 9 H), 1.56 - 1.76 (m, 4 H), 2.66 (s, 3 H), 2.82 (br s, 3 H), 3.18 (br s, 2 H), 4.15 (s, 2 H), 4.55 - 4.65 (m, 1 H), 6.72 (dd, J=9.3, 2.6 Hz, 1 H), 6.94 (dd, J=9.3, 2.6 Hz, 1 H), 7.18 - 7.40 (m, 5 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm -0.13 (s, 3 H), 0.06 (s, 3 H), 0.88 (s, 9 H), 1.43 (s, 9 H), 1.59 - 1.79 (m, 2 H), 1.90 (br s, 2 H), 2.55 (s, 3 H), 2.80 (br s, 3 H), 3.03 - 3.26 (m, 1 H), 3.39 (br s, 1 H), 3.87 - 4.07 (m, 2 H), 4.56 (s, 2 H), 4.63 (br s, 1 H), 6.53 (br s, 1 H), 6.67 (dd, J=10.0, 2.5 Hz, 1 H), 7.19 - 7.39 (m, 5 H)
MS (ESI pos.) m/z : 300 [M+Na]+,RT=0.900 min(分析条件4)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.55 (s, 9 H), 3.94 (s, 3 H), 8.20 (dd, J=8.9, 2.1 Hz, 1 H), 8.35 (d, J=2.1 Hz, 1 H), 8.54 (d, J=8.9 Hz, 1 H), 9.89 - 10.01 (m, 1 H), 10.59 (br s, 1 H)
MS (ESI pos.) m/z : 351 [M+H]+,RT=0.622 min(分析条件4)
MS (ESI pos.) m/z : 251 [M+H]+,RT=0.210 min(分析条件4)
製造例14-(4)で得られたメチル 4-アミノ-3-[(モルホリン-4-イル)メチル]ベンゾアート(粗生成物)のクロロホルム(50 mL)溶液に、TEA(2.05 mL)を加え、氷冷下、先に調整した酸クロライドのクロロホルム溶液を加え、室温にて17時間攪拌した。反応終了後、炭酸水素ナトリウム水溶液を加え反応をクエンチングした後、その有機層を飽和食塩水で洗浄、無水硫酸マグネシウムにて乾燥、減圧濃縮により粗生成物を得た。得られた粗生成物をカラムクロマトグラフィー(シリカゲルカートリッジ、n-ヘキサン:酢酸エチル=80:20~50:50)にて精製し、表題化合物(1.4 g)を無色固体として得た。
MS (ESI pos.) m/z : 393 [M+H]+,RT=0.374 min(分析条件4)
MS (ESI pos.) m/z : 337 [M+H]+,RT=0.575 min(分析条件2)
MS (ESI pos.) m/z : 176 [M+H]+,RT=0.416 min(分析条件3)
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 4.21 (br t, J=5.4 Hz, 1 H), 5.01 (d, J=5.4 Hz, 2 H), 6.70 (d, J=9.5 Hz, 1 H), 7.19 (t, J=7.6 Hz, 1 H), 7.43 (d, J=7.6 Hz, 1 H), 7.54 (d, J=7.6 Hz, 1 H), 7.83 (d, J=9.5 Hz, 1 H), 11.33 (br s, 1 H)
MS (ESI pos.) m/z : 190 [M+H]+,RT=0.528 min(分析条件3)
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.67 (d, J=6.6 Hz, 3 H), 4.80 - 4.90 (m, 1 H), 5.28 - 5.35 (m, 1 H), 6.63 (d, J=9.5 Hz, 1 H), 7.16 (t, J=7.6 Hz, 1 H), 7.32 (d, J=7.6 Hz, 1 H), 7.46 (d, J=7.6 Hz, 1 H), 7.77 (d, J=9.5 Hz, 1 H), 11.17 (br s, 1 H)
MS (ESI pos.) m/z : 265 [M+H]+,RT=1.139 min(分析条件3)
MS (ESI pos.) m/z : 235 [M+H]+,RT=0.712 min(分析条件3)
MS (ESI pos.) m/z : 189 [M+H]+,RT=0.716 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 1.27 (t, J=7.2 Hz, 3 H), 3.14 (qd, J=7.2, 4.5 Hz, 2 H), 5.72 (t, J=4.5 Hz, 1 H), 6.46 (d, J=9.5 Hz, 1 H), 6.67 (d, J=7.8 Hz, 1 H), 6.91 (dd, J=7.8, 0.8 Hz, 1 H), 7.02 (t, J=7.8 Hz, 1 H), 7.82 (d, J=9.5 Hz, 1 H), 10.98 (br s, 1 H)
MS (ESI pos.) m/z : 323[M+H]+,RT=0.969 min(分析条件3)
MS (ESI pos.) m/z : 309[M+H]+,RT=0.802 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 7.32 - 7.42 (m, 1 H), 7.49 (d, J=8.3 Hz, 1 H), 7.68 - 7.78 (m, 1 H), 7.85 (d, J=8.7 Hz, 2 H), 7.97 (d, J=8.7 Hz, 2 H), 8.03 (d, J=7.4 Hz, 1 H), 9.00 (s, 1 H), 12.43 (s, 1 H), 12.71 (s, 1 H), 12.78 (br s, 1 H)
MS (ESI neg.) m/z : 350 [M-H]-,RT=1.035 min(分析条件3)
MS (ESI pos.) m/z : 338 [M+H]+,RT=0.885 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.87 (d, J=4.5 Hz, 3 H), 6.18 (d, J=4.5 Hz, 1 H), 6.83 (d, J=7.8 Hz, 1 H), 7.19 - 7.24 (m, 1 H), 7.24 - 7.29 (m, 1 H), 7.52 (t, J=7.8 Hz, 1 H), 7.71 (d, J=7.8 Hz, 1 H), 7.95 (dd, J=7.8, 1.9 Hz, 1 H), 8.33 (t, J=1.9 Hz, 1 H), 8.90 (s, 1 H), 11.77 (s, 1 H), 12.30 (s, 1 H), 13.06 (br s, 1 H)
MS (ESI pos.) m/z : 419 [M+H]+,RT=0.641 min(分析条件3)
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 0.77 - 1.32 (m, 10 H), 2.20 (s, 3 H), 2.80 (s, 3 H), 3.00 - 3.11 (m, 1 H), 3.77 (s, 2 H), 6.76 - 6.92 (m, 1 H), 7.11 - 7.16 (m, 1 H), 7.16 - 7.21 (m, 1 H), 7.17 - 7.20 (m, 1 H), 7.22 - 7.39 (m, 4 H), 8.15 - 8.33 (m, 1 H), 8.96 (br s, 1 H), 11.71 (br s, 1 H)
MS (ESI pos.) m/z : 353 [M+H]+,RT=1.008 min(分析条件2)
MS (ESI pos.) m/z : 339 [M+H]+,RT=0.827 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.97 (d, J=4.5 Hz, 3 H), 7.08 (d, J=5.4 Hz, 1 H), 7.18 (br d, J=4.5 Hz, 1 H), 7.85 (d, J=8.7 Hz, 2 H), 7.92 (d, J=5.4 Hz, 1 H), 7.97 (d, J=8.7 Hz, 2 H), 8.85 (s, 1 H), 12.14 (s, 1 H), 12.30 (br s, 1 H), 12.82 (br s, 1 H)
MS (ESI pos.) m/z : 316 [M+H]+,RT=0.568 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.85 (s, 3 H), 6.85 (dd, J=7.6, 1.4 Hz, 1 H), 7.08 (s, 1 H), 7.16 (s, 1 H), 7.19 - 7.27 (m, 2 H), 7.53 (s, 1 H), 8.87 (s, 1 H), 9.00 (br s, 2 H), 11.83 (s, 1 H), 12.67 (s, 1 H)
MS (ESI pos.) m/z : 370 [M+H]+,RT=1.084 min(分析条件3)
MS (ESI neg.) m/z : 354 [M-H]-,RT=0.939 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.86 (d, J=4.5 Hz, 3 H), 6.54 (br d, J=4.5 Hz, 1 H), 6.63 (dd, J=11.6, 2.5 Hz, 1 H), 7.06 (dd, J=8.7, 2.5 Hz, 1 H), 7.83 (d, J=8.7 Hz, 2 H), 7.97 (d, J=8.7 Hz, 2 H), 8.87 (s, 1 H), 12.53 (br s, 1 H)
MS (ESI pos.) m/z : 523 [M+H]+,RT=0.989 min(分析条件3)
MS (ESI pos.) m/z : 423 [M+H]+,RT=0.497 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.86 (d, J=4.5 Hz, 3 H), 4.31 (d, J=5.4 Hz, 2 H), 6.16 (br d, J=4.5 Hz, 1 H), 6.18 (s, 1 H), 6.82 (d, J=6.6 Hz, 1 H), 6.85 (s, 2 H), 7.16 - 7.27 (m, 2 H), 7.37 (t, J=6.6 Hz, 1 H), 8.61 (s, 2 H), 8.86 (s, 1 H), 11.69 (br s, 2 H)
MS (ESI pos.) m/z : 552 [M+H]+,RT=1.060 min(分析条件3)
MS (ESI pos.) m/z : 538 [M+H]+,RT=0.944 min(分析条件3)
MS (ESI pos.) m/z : 438 [M+H]+,RT=0.368 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 1.76 - 1.86 (m, 2 H), 2.06 - 2.14 (m, 2 H), 2.86 (s, 3 H), 3.79 - 3.85 (m, 2 H), 4.00 - 4.08 (m, 2 H), 6.21 (br s, 1 H), 6.83 (d, J=7.4 Hz, 1 H), 7.18 - 7.24 (m, 2 H), 8.76 (s, 2 H), 8.87 (s, 1 H), 11.71 (s, 1 H), 11.77 (s, 1 H)
MS (ESI pos.) m/z : 468 [M+H]+,RT=0.543 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.42 - 2.49 (m, 4 H), 2.86 (d, J=4.5 Hz, 3 H), 3.09 - 3.22 (m, 2 H), 3.36 - 3.41 (m, 2 H), 3.56 - 3.60 (m, 4 H), 6.55 (br d, J=4.5 Hz, 1 H), 6.65 (dd, J=11.6, 2.5 Hz, 1 H), 7.07 (dd, J=8.3, 2.5 Hz, 1 H), 7.81 (d, J=8.7 Hz, 2 H), 7.87 (d, J=8.7 Hz, 2 H), 8.35 (t, J=5.6 Hz, 1 H), 8.88 (s, 1 H), 11.86 (br s, 1 H), 12.32 (s, 1 H)
反応液を分取LCMSにて精製し、表題化合物(9 mg)を橙色固体として得た。
MS (ESI pos.) m/z : 498 [M+H]+,RT=1.147 min(分析条件3)
MS (ESI pos.) m/z : 398 [M+H]+,RT=0.517 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.85 (s, 3 H), 3.15 - 3.19 (m, 4 H), 3.92 - 3.99 (m, 4 H), 6.63 (dd, J=11.6, 2.5 Hz, 1 H), 7.04 (dd, J=8.7, 2.5 Hz, 1 H), 8.79 (s, 2 H), 8.85 (s, 1 H), 9.26 (br s, 1 H), 11.82 (s, 1 H), 11.88 (br s, 1 H)
MS (ESI pos.) m/z : 543 [M+H]+,RT=1.194 min(分析条件3)
MS (ESI pos.) m/z : 529 [M+H]+,RT=1.078 min(分析条件3)
MS (ESI pos.) m/z : 429 [M+H]+,RT=0.601 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.07 (br s, 2 H), 2.86 (d, J=4.4 Hz, 3 H), 3.00 - 3.07 (m, 2 H), 4.15 (br t, J=5.4 Hz, 2 H), 6.55 (d, J=4.4 Hz, 1 H), 6.61 (dd, J=8.8, 2.6 Hz, 1 H), 7.01 (dd, J=8.8, 2.6 Hz, 1 H), 7.14 (dd, J=8.4, 1.7 Hz, 1 H), 7.51 (d, J=1.7 Hz, 1 H), 7.71 (d, J=8.4 Hz, 1 H), 8.82 (s, 1 H), 12.38 (br s, 1 H)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.86 (d, J=4.4 Hz, 3 H), 6.56 (br d, J=4.4 Hz, 1 H), 6.66 (dd, J=11.8, 2.6 Hz, 1 H), 7.07 (dd, J=8.7, 2.6 Hz, 1 H), 8.92 (s, 1 H), 9.32 (s, 2 H), 11.89 (br s, 1 H), 12.44 (s, 1 H), 13.39 (br s, 1 H)
MS (ESI neg.) m/z : 399 [M-H]-,RT=0.678 min(分析条件3)
MS (ESI pos.) m/z : 581[M+H]+,RT=1.283 min(分析条件3)
MS (ESI pos.) m/z : 343 [M+H]+,RT=0.474 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.86 (s, 3 H), 4.75 (s, 2 H), 6.60 (br s, 1 H), 6.64 - 6.68 (m, 1 H), 7.05 - 7.10 (m, 1 H), 7.82 (d, J=5.4 Hz, 1 H), 8.54 (d, J=5.4 Hz, 1 H), 8.93 (s, 1 H), 9.47 (s, 1 H), 12.01 (br s, 1 H), 12.35 (s, 1 H)
MS (ESI neg.) m/z : 453 [M-H]-,RT=0.926 min(分析条件3)
MS (ESI pos.) m/z : 371 [M+H]+,RT=0.738 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.85 (d, J=4.6 Hz, 3 H), 6.38 - 6.53 (m, 2 H), 6.89 (br d, J=8.6 Hz, 1 H), 7.78 (s, 4 H), 8.72 (s, 1 H), 8.94 (br s, 1 H), 11.14 (br s, 1 H), 11.86 (br s, 1 H), 13.43 (s, 1 H)
MS (ESI pos.) m/z : 496 [M+H]+,RT=0.824 min(分析条件3)
MS (ESI pos.) m/z : 482 [M+H]+,RT=0.680 min(分析条件3)
1H NMR (400 MHz, Pyridine-d5) δ ppm 0.96 - 1.76 (m, 10 H), 2.41 (s, 3 H), 2.68 (br t, J=11.7 Hz, 1 H), 2.95 (s, 3 H), 3.86 - 3.97 (m, 2 H), 6.61 (dd, J=11.6, 2.5 Hz, 1 H), 7.13 (dd, J=9.5, 2.5 Hz, 1 H), 8.42 (d, J=1.7 Hz, 1 H), 8.49 - 8.57 (m, 1 H), 8.87 (d, J=8.6 Hz, 1 H), 13.53 (br s, 1 H)
MS (ESI pos.) m/z : 698[M+H]+,RT=0.820 min(分析条件3)
MS (ESI pos.) m/z : 478[M+H]+,RT=0.206 min(分析条件3)
MS (ESI pos.) m/z : 464 [M+H]+,RT=0.618 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 0.98 - 2.24 (m, 10 H), 2.64 - 2.73 (m, 1 H), 2.91 (d, J=4.8 Hz, 3 H), 3.78 (br s, 3 H), 4.40 (s, 2 H), 6.19 (br s, 1 H), 7.84 - 8.11 (m, 3 H), 8.42 (d, J=8.1 Hz, 1 H), 8.53 (br s, 1 H), 8.99 (s, 1 H), 12.10 (br s, 2 H), 12.87 (br s, 1 H)
MS (ESI pos.) m/z : 624[M+H]+,RT=0.985 min(分析条件3)
MS (ESI pos.) m/z : 468 [M+H]+,RT=0.573 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 1.31 - 2.17 (m, 9 H), 2.86 (s, 3 H), 3.57 (s, 2 H), 6.60 - 6.76 (m, 2 H), 7.10 (br d, J=7.9 Hz, 1 H), 7.61 - 7.81 (m, 1 H), 8.37 - 8.43 (m, 1 H), 8.53 (br d, J=8.6 Hz, 1 H), 8.92 (br s, 1 H), 12.21 (br s, 1 H), 12.69 (br s, 1 H)
MS (ESI pos.) m/z : 523[M+H]+,RT=1.177 min(分析条件4)
MS (ESI pos.) m/z : 467 [M+H]+,RT=1.217 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 1.02 - 1.22 (m, 3 H), 1.29 - 1.41 (m, 2 H), 1.48 - 1.56 (m, 1 H), 1.66 - 1.75 (m, 2 H), 1.84 - 1.92 (m, 2 H), 2.64 (s, 3 H), 2.76 - 2.83 (m, 1 H), 2.85 (s, 3 H), 6.63 (dd, J=11.7, 2.6 Hz, 1 H), 7.06 (dd, J=8.8, 2.6 Hz, 1 H), 7.75 (dd, J=8.6, 2.0 Hz, 1 H), 7.81 (d, J=2.0 Hz, 1 H), 8.66 (d, J=8.6 Hz, 1 H), 8.89 (s, 1 H), 11.82 (s, 1 H), 12.70 (s, 1 H)
MS (ESI pos.) m/z : 550 [M+H]+,RT=0.980 min(分析条件4)
MS (ESI pos.) m/z : 518 [M+H]+,RT=1.233 min(分析条件4)
MS (ESI neg.) m/z : 426 [M-H]-,RT=1.456 min(分析条件3)
MS (ESI pos.) m/z : 372 [M+H]+,RT=1.133 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.84 (d, J=4.2 Hz, 3 H), 6.54 (br d, J=4.2 Hz, 1 H), 6.66 (dd, J=11.5, 1.8 Hz, 1 H), 6.92 (dd, J=8.4, 1.8 Hz, 1 H), 7.78 (br d, J=8.6 Hz, 2 H), 7.99 (br d, J=8.6 Hz, 2 H), 11.32 (s, 1 H), 12.86 (br s, 1 H), 12.93 (s, 1 H), 16.06 (s, 1 H)
MS (ESI pos.) m/z : 700 [M+H]+,RT=1.048 min(分析条件4)
MS (ESI neg.) m/z : 666 [M-H]-,RT=0.997 min(分析条件4)
MS (ESI pos.) m/z : 704 [M+Na]+,RT=1.057 min(分析条件4)
MS (ESI neg.) m/z : 590 [M-H]-,RT=0.951 min(分析条件4)
MS (ESI pos.) m/z : 482 [M+H]+,RT=0.872 min(分析条件3)
MS (ESI pos.) m/z : 386 [M+H]+,RT=0.811 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.82 (d, J=4.5 Hz, 3 H), 4.04 (s, 3 H), 6.32 (d, J=4.5 Hz, 1 H), 6.54 (dd, J=11.5, 2.6 Hz, 1 H), 6.82 (dd, J=9.5, 2.6 Hz, 1 H), 7.77 (d, J=8.6 Hz, 2 H), 7.92 (d, J=8.6 Hz, 2 H), 10.83 (br s, 1 H), 11.04 (s, 1 H)
MS (ESI pos.) m/z : 596 [M+H]+,RT=1.295 min(分析条件4)
MS (ESI pos.) m/z : 482 [M+H]+,RT=1.256 min(分析条件3)
MS (ESI pos.) m/z : 426 [M+H]+,RT=0.926 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 0.76 - 0.91 (m, 2 H), 2.86 (br d, J=3.7 Hz, 3 H), 3.29 - 3.36 (m, 2 H), 3.56 - 3.66 (m, 1 H), 6.46 - 6.54 (m, 1 H), 6.66 (br d, J=11.4 Hz, 1 H), 6.75 - 6.87 (m, 2 H), 7.10 (dd, J=8.4, 2.7 Hz, 1 H), 7.87 (br d, J=8.4 Hz, 1 H), 8.04 (s, 1 H), 8.54 (d, J=8.4 Hz, 1 H), 8.93 (s, 1 H), 12.05 (s, 1 H), 12.55 (s, 1 H)
MS (ESI pos.) m/z : 484 [M+H]+,RT=1.249 min(分析条件3)
MS (ESI pos.) m/z : 428 [M+H]+,RT=0.913 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 1.51 - 1.71 (m, 4 H), 2.80 (br t, J=7.4 Hz, 2 H), 2.86 (s, 3 H), 3.44 (t, J=6.4 Hz, 2 H), 6.65 (dd, J=11.7, 2.6 Hz, 1 H), 7.09 (dd, J=8.7, 2.6 Hz, 1 H), 7.80 - 7.88 (m, 2 H), 8.55 (d, J=9.2 Hz, 1 H), 8.93 (s, 1 H), 12.02 (s, 1 H), 12.48 (s, 1 H)
MS (ESI pos.) m/z : 522 [M+H]+,RT=1.210 min(分析条件3)
MS (ESI neg.) m/z : 488 [M-H]-,RT=1.175 min(分析条件4)
MS (ESI neg.) m/z : 398 [M-H]-,RT=1.025 min(分析条件4)
1H NMR (400 MHz, DMSO-d6) δ ppm 1.33 (br t, J=7.3 Hz, 3 H), 2.84 (s, 3 H), 4.32 (q, J=7.3 Hz, 2 H), 6.53 - 6.74 (m, 2 H), 6.86 - 7.00 (m, 1 H), 7.82 (d, J=8.4 Hz, 2 H), 8.00 (d, J=8.4 Hz, 2 H), 11.36 (br s, 1 H), 12.96 (br s, 1 H), 16.03 (s, 1 H)
MS (ESI pos.) m/z : 601[M+H]+,RT=0.960 min(分析条件3)
MS (ESI pos.) m/z : 481[M+H]+,RT=0.693 min(分析条件3)
MS (ESI pos.) m/z : 467 [M+H]+,RT=0.608 min(分析条件3)
1H NMR (400 MHz, METHANOL-d4) δ ppm 1.10 - 1.24 (m, 2 H), 1.24 - 1.38 (m, 2 H), 1.43 - 1.56 (m, 2 H), 1.62 - 1.71 (m, 1 H), 1.81 - 1.90 (m, 2 H), 1.97 - 2.05 (m, 2 H), 2.44 (br s, 3 H), 2.91 (s, 3 H), 4.06 (br s, 2 H), 4.40 (s, 2 H), 6.50 - 6.55 (m, 1 H), 6.60 (d, J=6.7 Hz, 1 H), 6.69 (d, J=8.4 Hz, 1 H), 7.75 - 7.87 (m, 2 H), 8.49 (s, 1 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm -0.20 (s, 3 H), -0.12 (br s, 3 H), 0.84 (s, 9 H), 1.45 (s, 9 H), 1.60 (s, 9 H), 1.86 (br s, 1 H), 1.96 (br s, 1 H), 2.69 (s, 3 H), 2.79 (s, 3 H), 2.98 - 3.38 (m, 4 H), 3.90 - 4.26 (m, 2 H), 4.71 (br t, J=5.5 Hz, 1 H), 6.67 - 6.80 (m, 1 H), 6.81 - 6.96 (m, 1 H), 7.14 - 7.39 (m, 5 H), 7.63 (br d, J=8.6 Hz, 2 H), 7.93 (d, J=8.6 Hz, 2 H), 8.36 (br s, 1 H), 10.15 (br s, 1 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.42 (s, 9 H), 1.59 (s, 9 H), 2.63 (s, 3 H), 2.77 (s, 3 H), 3.07 (br s, 2 H), 3.16 (br s, 2 H), 3.56 (br s, 2 H), 4.12 (s, 2 H), 4.61 (br d, J=6.2 Hz, 1 H), 6.63 - 6.81 (m, 1 H), 6.86 - 7.01 (m, 1 H), 7.16 - 7.38 (m, 5 H), 7.57 (br d, J=8.6 Hz, 2 H), 7.92 (d, J=8.6 Hz, 2 H), 8.27 (br s, 1 H), 9.79 (br s, 1 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.36 - 1.48 (m, 9 H), 1.58 (s, 9 H), 2.66 (m, 3 H), 2.88 (s, 3 H), 3.09 (br s, 2 H), 3.26 (br s, 2 H), 3.52 - 3.61 (m, 2 H), 4.03 (s, 2 H), 6.82 - 7.03 (m, 1 H), 7.16 - 7.41 (m, 6 H), 7.64 (br d, J=8.6 Hz, 2 H), 7.93 (d, J=8.6 Hz, 2 H), 8.57 (br, 1 H), 9.42 (br, 1 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.48 (s, 9 H), 1.58 (s, 9 H), 2.69 (s, 3 H), 2.91 - 3.13 (m, 2 H), 3.41 - 3.73 (m, 5 H), 4.08 (br s, 2 H), 7.24 - 7.40 (m, 5 H), 7.57 (br d, J=8.2 Hz, 1 H), 7.76 (d, J=8.7 Hz, 2 H), 7.85 - 7.94 (m, 1 H), 7.99 (d, J=8.7 Hz, 2 H), 9.73 (br s, 1 H), 11.23 (br s, 1 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.31 (br s, 9 H), 1.43 (br s, 9 H), 2.57 (br s, 3 H), 2.66 - 2.83 (m, 4 H), 2.93 (br s, 1 H), 3.23 (br s, 2 H), 6.09 - 6.28 (m, 1 H), 6.74 - 7.02 (m, 2 H), 7.85 (br s, 4 H), 9.64 (br s, 1 H), 10.30 (br s, 1 H)
MS (ESI pos.) m/z : 413 [M+H]+,RT=0.695 min(分析条件2)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.61 (t, J=5.4 Hz, 2 H), 2.84 (s, 3 H), 3.10 (br s, 5 H), 6.39 (br s, 1 H), 6.60 (br d, J=10.0 Hz, 1 H), 7.03 (dd, J=10.0, 2.3 Hz, 2 H), 7.83 (d, J=8.9 Hz, 2 H), 7.96 (d, J=8.9 Hz, 2 H), 8.47 (br s, 1 H), 10.86 (s, 1 H), 11.36 (br s, 1 H), 12.81 (br s, 1 H)
MS (ESI pos.) m/z : 822 [M+H]+,RT=1.120 min(分析条件4)
MS (ESI pos.) m/z : 810 [M+H]+,RT=1.056 min(分析条件4)
MS (ESI pos.) m/z : 742 [M+Na]+,RT=0.956 min(分析条件4)
MS (ESI pos.) m/z : 414 [M+H]+,RT=0.479 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.82 (d, J=4.3 Hz, 3 H), 2.93 (br t, J=5.9 Hz, 2 H), 3.67 (br t, J=5.9 Hz, 2 H), 6.42 (br d, J=4.3 Hz, 1 H), 6.57 (dd, J=11.4, 2.3 Hz, 1 H), 7.10 (dd, J=10.8, 2.3 Hz, 1 H), 7.74 (d, J=8.7 Hz, 2 H), 7.91 (d, J=8.7 Hz, 2 H), 12.70 (br s, 1 H)
MS (ESI pos.) m/z : 427 [M+H]+,RT=0.722 min(分析条件2)
1H NMR (400 MHz, DMSO-d6) δ ppm 1.78 - 2.00 (m, 2 H), 2.72 - 2.90 (m, 8 H), 3.00 (br s, 2 H), 6.36 (br s, 1 H), 6.58 (br d, J=10.3 Hz, 1 H), 6.94 (dd, J=10.3, 2.3 Hz, 1 H), 7.81 (d, J=8.8 Hz, 2 H), 7.95 (d, J=8.8 Hz, 2 H), 8.29 (br s, 1 H), 10.79 (s, 1 H), 11.27 (br s, 1 H), 12.08 (br s, 1 H)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.68 (s, 3 H), 4.22 (br s, 2 H), 7.12 - 7.53 (m, 7 H), 7.78 (br d, J=8.4 Hz, 2 H), 7.98 (br d, J=8.4 Hz, 2 H), 10.48 - 11.49 (m, 1 H), 12.23 - 13.35 (m, 2 H)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.69 (s, 3 H), 3.18 (s, 3 H), 4.22 (s, 2 H), 6.85 - 7.51 (m, 7 H), 7.78 (d, J=8.8 Hz, 2 H), 8.02 (d, J=8.8 Hz, 2 H), 10.76 - 11.33 (m, 1 H), 12.70 - 13.16 (m, 1 H)
MS (ESI pos.) m/z : 449 [M+H]+,RT=0.797 min(分析条件4)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.85 (br d, J=4.3 Hz, 3 H), 3.32 (s, 3 H), 6.54 (br s, 1 H), 6.61 - 6.75 (m, 1 H), 6.85 - 7.01 (m, 1 H), 7.79 (br d, J=8.7 Hz, 2 H), 8.01 (br d, J=8.7 Hz, 2 H), 11.22 - 11.41 (m, 1 H), 12.83 - 13.01 (m, 1 H)
MS (ESI pos.) m/z : 461 [M+H]+,RT=1.189 min(分析条件3)
MS (ESI pos.) m/z : 443 [M+H]+,RT=1.430 min(分析条件3)
MS (ESI pos.) m/z : 476 [M+H]+,RT=0.879 min(分析条件3)
MS (ESI neg.) m/z : 500 [M-H]-,RT=1.311 min(分析条件3)
MS (ESI pos.) m/z : 370 [M+H]+,RT=0.636 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.83 (br d, J=4.1 Hz, 3 H), 6.53 - 6.70 (m, 1 H), 6.79 - 6.96 (m, 1 H), 7.84 - 7.93 (m, 4 H), 8.84 - 9.03 (m, 2 H), 9.17 - 9.35 (m, 2 H), 11.32 (br s, 1 H), 13.09 (br s, 1 H)
MS (ESI pos.) m/z : 485 [M+H]+,RT=1.093 min(分析条件3)
MS (ESI pos.) m/z : 389 [M+H]+,RT=0.755 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.86 (d, J=4.5 Hz, 3 H), 3.06 (s, 3 H), 4.14 (s, 1 H), 6.55 (br d, J=4.5 Hz, 1 H), 6.65 (dd, J=11.6, 2.5 Hz, 1 H), 7.07 (dd, J=8.7, 2.5 Hz, 1 H), 7.91 - 7.96 (m, 4 H), 8.89 (s, 1 H), 11.87 (br s, 1 H), 12.47 (br s, 1 H)
MS (ESI/APCI pos.) m/z : 602 [M+H]+,RT=3.28-3.36 min(分析条件1)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 2.67 (s, 3 H), 3.94 (s, 3 H), 4.09 (s, 2 H), 5.59 (d, J=11.5 Hz, 1 H), 5.86 (d, J=17.2 Hz, 1 H), 7.08 (dd, J=17.2, 11.5 Hz, 1 H), 7.21 (dd, J=8.7, 2.6 Hz, 1 H), 7.24 - 7.45 (m, 5 H), 7.59 (dd, J=8.7, 2.6 Hz, 1 H), 8.00 (dd, J=8.6, 2.0 Hz, 1 H), 8.20 (d, J=2.0 Hz, 1 H), 8.33 (d, J=8.6 Hz, 1 H), 9.20 (s, 1 H), 12.54 (s, 1 H)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 2.66 (s, 3 H), 3.97 (s, 3 H), 4.09 (s, 2 H), 7.20 (dd, J=9.0, 2.6 Hz, 1 H), 7.26 - 7.38 (m, 5 H), 7.57 (dd, J=8.0, 2.6 Hz, 1 H), 8.28 (dd, J=8.6, 2.1 Hz, 1 H), 8.46 (d, J=2.1 Hz, 1 H), 8.82 (d, J=8.6 Hz, 1 H), 9.18 (s, 1 H), 10.12 (s, 1 H)
MS (ESI pos.) m/z : 573 [M+H]+,RT=0.683 min(分析条件4)
MS (ESI pos.) m/z : 483 [M+H]+,RT=0.772 min(分析条件3)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.16 - 1.36 (m, 2 H)1.40 - 1.70 (m, 4 H), 2.41 (br s, 4 H), 2.58 (br s, 3 H), 3.49 (s, 2 H), 3.94 (s, 3 H), 5.50 (br s, 1 H), 6.44 (br dd, J=9.6, 1.9 Hz, 1 H), 7.10 (br dd, J=9.6, 1.9 Hz, 1 H), 7.93 (d, J=1.3 Hz, 1 H), 8.00 - 8.11 (m, 1 H), 8.20 (d, J=8.6 Hz, 1 H), 11.94 (br s, 1 H), 12.30 (br s, 1 H)
MS (ESI pos.) m/z : 589 [M+H]+,RT=0.715 min(分析条件4)
MS (ESI pos.) m/z : 499 [M+H]+,RT=0.679 min(分析条件4)
MS (ESI pos.) m/z : 471 [M+H]+,RT=0.715 min(分析条件3)
1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (br s, 4 H), 2.84 (d, J=4.4 Hz, 3 H), 3.49 - 3.72 (m, 6 H), 6.56 (br d, J=4.4 Hz, 1 H), 6.61 - 6.69 (m, 1 H), 6.91 (dd, J=8.8, 2.3 Hz, 1 H), 7.88 (br s, 1 H), 7.93 (br d, J=8.6 Hz, 1 H), 8.27 (d, J=8.6 Hz, 1 H), 11.11 (br s, 1 H), 12.70 (br s, 1 H), 12.94 (br s, 1 H)
MS (ESI pos.) m/z : 411 [M+H]+,RT=0.923 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.85 (br d, J=4.5 Hz, 3 H), 6.01 (s, 1 H), 6.55 (br d, J=4.5 Hz, 1 H), 6.64 (br d, J=11.6 Hz, 1 H), 7.06 (br d, J=8.7 Hz, 1 H), 7.38 - 7.48 (m, 2 H), 7.76 - 7.86 (m, 2 H), 8.88 (s, 1 H), 11.86 (br s, 1 H), 12.24 (s, 1 H)
MS (ESI pos.) m/z : 395 [M+H]+,RT=1.204 min(分析条件3)
MS (ESI neg.) m/z : 337 [M-H]-,RT=0.859 min(分析条件3)
MS (ESI neg.) m/z : 323 [M-H]-,RT=0.754 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 7.11 - 7.19 (m, 2 H), 7.40 - 7.51 (m, 1 H), 7.84 (d, J=8.7 Hz, 2 H), 7.97 (d, J=8.7 Hz, 2 H), 8.94 (s, 1 H), 10.77 (br s, 1 H), 11.71 (br s, 1 H), 12.53 (s, 1 H), 12.69 (br s, 1 H)
MS (ESI pos.) m/z : 356 [M+H]+,RT=0.941 min(分析条件3)
MS (ESI pos.) m/z : 342 [M+H]+,RT=0.791 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 2.81 (d, J=4.5 Hz, 3 H), 4.21 (br d, J=5.4 Hz, 2 H), 6.26 (br d, J=4.5 Hz, 1 H), 6.44 (dd, J=12.0, 2.5 Hz, 1 H), 6.59 (d, J=9.1 Hz, 2 H), 6.67 (dd, J=9.1, 2.5 Hz, 1 H), 6.91 (br t, J=5.4 Hz, 1 H), 7.61 (s, 1 H), 7.66 (d, J=9.1 Hz, 2 H), 11.11 (br s, 1 H), 12.00 (br s, 1 H)
MS (ESI pos.) m/z : 354 [M+H]+,RT=0.884 min(分析条件3)
MS (ESI pos.) m/z : 324 [M+H]+,RT=0.748 min(分析条件3)
1H NMR (600 MHz, DMSO-d6) δ ppm 5.78 (br s, 2 H), 6.98 (d, J=7.6 Hz, 1 H), 7.10 (dd, J=8.3, 7.8 Hz, 1 H), 7.22 (d, J=7.0 Hz, 1 H), 7.51 (dd, J=7.6, 7.0 Hz, 1 H), 7.70 (d, J=7.8 Hz, 1 H), 7.95 (d, J=8.3 Hz, 1 H), 8.30 (s, 1 H), 8.87 (s, 1 H), 11.76 (br s, 1 H), 12.32 (s, 1 H), 13.05 (br s, 1 H)
大腸菌DNAジャイレース酵素活性は、ATP存在下、DNAジャイレースとその基質であるrelaxed pBR322(Inspiralis社)を反応させ、反応後のsupercoiled pBR322/relaxed pBR322の比をH19(Profoldin社)で検出することによって測定した。
大腸菌DNAジャイレース酵素活性は、ATP存在下、DNAジャイレースとその基質であるrelaxed pBR322(Inspiralis社)を反応させ、反応後のsupercoiled pBR322/relaxed pBR322の比をH19で検出することによって測定した。
大腸菌トポイソメラーゼIV酵素活性は、ATP存在下、トポイソメラーゼIVとその基質であるsupercoiled pBR322(Inspiralis社)を反応させ、反応後のsupercoiled pBR322/relaxed pBR322の比をH19で検出することによって測定した。
最小発育阻止濃度(MIC)測定はCLSI(Clinical & Laboratory Standards Institute)標準法に準じ、下記に示す微量液体希釈法を用いた。
最小発育阻止濃度(MIC)測定はGeersらの方法(Antimicrob.Agents.Chemother.(1989),33,233-234.)に準じ、下記に示す微量液体希釈法を用いた。
Claims (21)
- 式[1]
Zは、NH-R1、C1-4アルキル基(該C1-4アルキル基は、アミノ基又はヒドロキシ基で置換されてもよい。)又はヒドロキシ基を示し、
R1は、水素原子又はC1-4アルキル基を示し、
T、U、V及びWは、全てがC-R2又はどれか1つがNでそれ以外はC-R2を示し、
R2は、水素原子、ハロゲン原子、ヒドロキシ基、C1-6アルキル基、C1-6アルコキシ基(該C1-6アルキル基及び該C1-6アルコキシ基は、-N(R21)(R22)で置換されてもよい。)又はアミノ基[該アミノ基は、C1-6アルキル基(該C1-6アルキル基は、ピペリジン-4-イル基、ピロリジン-3-イル基、アゼチジン-3-イル基、1-アミノ-シクロブタン-3-イル基、モルホリニル基又は-N(R23)(R24)で置換されてもよい。)、1-アミノ-シクロブタン-3-イル基又は式[2]に記載の置換基のいずれかで置換されてもよい。]を示し、
L1は、-CONR3-、-COO-、-(CH2)nNR3-又は-NR3CO-を示し、
R3は、水素原子又はC1-6アルキル基を示し、
nは1から4の整数を示し、
L2は、結合手、C1-6アルキレン基、ピペリジンジイル基、ピロリジンジイル基及びアゼチジンジイル基(該C1-6アルキレン基、該ピペリジンジイル基、該ピロリジンジイル基及び該アゼチジンジイル基は、カルボキシ基又はオキソ基で置換されてもよい。)からなる群から選ばれる基を示し、
Aは、アリール基、ヘテロ環基又はC3-8シクロアルキル基(該アリール基、該ヘテロ環基及び該C3-8シクロアルキル基は、下記の置換基群Raより同一に又は異なって選ばれる1個から4個の置換基で置換されてもよい。)を示し、
置換基群Raは、C1-6アルキル基(該C1-6アルキル基は、カルボキシ基、ヒドロキシ基、C3-8シクロアルキル基、カルバモイル基及び-N(R11)(R12)からなる群から選ばれる1個から2個の置換基で置換されてもよい。)、カルボキシ基、ヒドロキシ基、ヘテロ環基、アミジノ基、-N(R13)(R14)、-CON(R15)(R16)、C1-6アルコキシ基(該C1-6アルコキシ基は、アミノ基、N-メチルピペラジニル基及びモルホリニル基から選ばれる1個から2個の置換基で置換されてもよい。)、C2-6アルケニル基(該C2-6アルケニル基は、ヒドロキシ基又は-N(R17)(R18)で置換されてもよい。)、-COOR19、3-アミノアゼチジニル基、ピペラジニル基(該ピペラジニル基は、1個のメチル基で置換されてもよい。)、4-アミノピペリジニル基又は式[3]に記載の置換基のいずれかを示し、
R11及びR12は、結合する窒素原子と一緒になって、飽和の3員環から7員環を形成してもよく、ここで、該飽和の3員環から7員環は、環内にさらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよく、また、該飽和の3員環から7員環は、アミノ基で置換されてもよく、
R13及びR14は、同一に又は異なって水素原子、C1-6アルコキシカルボニル基、C3-8シクロアルキル基、-CONHSO2Me、C1-6アルキル基[該C1-6アルキル基は、アミノ基、N-メチルピペラジニル基、モルホリニル基、-N(CH2CH2OH)2及びヘテロ環基(該ヘテロ環基は、アミノ基で置換されてもよい。)から選ばれる1個から2個の置換基で置換されてもよい。]を示し、
R15及びR16は、同一に又は異なって水素原子、ヒドロキシ基、1,3-ジヒドロキシプロパン-2-イル基、メタンスルホニル基、N,N-ジメチルスルファモイル基及びC1-6アルキル基(該C1-6アルキル基は、アミノ基、モルホリニル基、ピペリジニル基、カルボキシ基、ヒドロキシ基及び式[4]に記載の置換基からなる群より同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)を示すか、又は、
R17及びR18は、同一に又は異なって水素原子又はC1-6アルキル基を示し、
R19は、C1-6アルキル基を示し、
R20は、水素原子又はC1-6アルキル基を示す。}
で表される化合物又はその薬学的に許容される塩。 - ZがNH-R1、C1-4アルキル基又はヒドロキシ基であり、R1がC1-4アルキル基である、請求項1に記載の化合物又はその薬学的に許容される塩。
- ZがNH-R1、エチル基又はヒドロキシ基であり、R1がメチル基である、請求項2に記載の化合物又はその薬学的に許容される塩。
- ZがNH-R1であり、R1がメチル基である、請求項3に記載の化合物又はその薬学的に許容される塩。
- T、U、V及びWがC-R2である、請求項4に記載の化合物又はその薬学的に許容される塩。
- L1が-CONR3-、-COO-又は-(CH2)nNR3-である、請求項5に記載の化合物又はその薬学的に許容される塩。
- L1が-CONR3-である、請求項6に記載の化合物又はその薬学的に許容される塩。
- R3が水素原子である、請求項7に記載の化合物又はその薬学的に許容される塩。
- L2が結合手、メチレン基又はエチレン基、ピペリジンジイル基、ピロリジンジイル基、アゼチジンジイル基からなる群から選ばれる結合手又は基である、請求項8に記載の化合物又はその薬学的に許容される塩。
- L2が結合手又はエチレン基である、請求項9に記載の化合物又はその薬学的に許容される塩。
- L2が結合手である、請求項10に記載の化合物又はその薬学的に許容される塩。
- T、U、V及びWがC-R2であり、各R2が、独立的に、水素原子、ハロゲン原子、ヒドロキシ基、C1-6アルキル基(該C1-6アルキル基は、-N(R21)(R22)で置換されてもよい。)、C1-6アルコキシ基又はアミノ基[該アミノ基は、C1-6アルキル基(該C1-6アルキル基は、ピペリジン-4-イル基、ピロリジン-3-イル基、アゼチジン-3-イル基、1-アミノ-シクロブタン-3-イル基、モルホリノ基又は-N(R23)(R24)で置換されてもよい。)、1-アミノ-シクロブタン-3-イル基又は式[2]に記載の置換基のいずれかで置換されてもよい。]であり、
- 各R2が、独立的に、水素原子、フッ素原子、ヒドロキシ基、エチル基、n-プロピル基(該エチル基及び該n-プロピル基は、-N(R21)(R22)で置換されてもよい。)、C1-6アルコキシ基、アミノ基[該アミノ基は、メチル基、エチル基、n-プロピル基(該メチル基、該エチル基及び該n-プロピル基は、ピペリジン-4-イル基、ピロリジン-3-イル基、アゼチジン-3-イル基、1-アミノ-シクロブタン-3-イル基、モルホリノ基及び-N(R23)(R24)からなる群から選ばれる1個から2個の置換基で置換されてもよい。)、1-アミノ-シクロブタン-3-イル基又は式[2]に記載の置換基のいずれかで置換されてもよい。]であり、
- 各R2が、独立的に、水素原子、フッ素原子又はヒドロキシ基である、請求項13に記載の化合物又はその薬学的に許容される塩。
- UがC-F又はC-Hであり、T及びVがC-Hであり、WがC-R2である、請求項13に記載の化合物又はその薬学的に許容される塩。
- Aが、アリール基又はヘテロ環基(該アリール基及び該ヘテロ環基は、置換基群Raより同一に又は異なって選ばれる1から4個の置換基で置換されてもよい。)である、請求項1から15のいずれか1項に記載の化合物又はその薬学的に許容される塩。
- Aが、アリール基又はヘテロ環基(該アリール基及び該ヘテロ環基は、置換基群Rbより同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)であり、
Rbは、C1-6アルキル基(該C1-6アルキル基は、カルボキシ基、ヒドロキシ基、カルバモイル基及び-N(R11)(R12)からなる群より同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)、カルボキシ基、ヒドロキシ基、ヘテロ環基、アミジノ基、-N(R13)(R14)、-CON(R15)(R16)、C1-6アルコキシ基(該C1-6アルコキシ基は、アミノ基、N-メチルピペラジニル基又はモルホリノ基で置換されてもよい。)、C2-6アルケニル基(該C2-6アルケニル基は、ヒドロキシ基又は-N(R17)(R18)で置換されてもよい。)、3-アミノアゼチジノ基、ピペラジニル基(該ピペラジニル基は、1個のメチル基で置換されてもよい。)、4-アミノピペリジノ基又は式[3]に記載の置換基のいずれかであり、
R11及びR12が結合する窒素原子と一緒になって、形成する飽和の3員環から7員環は、アゼチジニル基、ピロリジニル基、ピペリジニル基又はモルホリノ基であり、
R13及びR14は、同一に又は異なって水素原子、t-ブトキシカルボニル基、シクロヘキシル基、-CONHSO2Me、メチル基、エチル基又はn-プロピル基(該メチル基、該エチル基及び該n-プロピル基は、アミノ基、N-メチルピペラジノ基、モルホリニル基、-N(CH2CH2OH)2及びヘテロ環基からなる群から選ばれる1個から2個の置換基で置換されてもよい。)であり、
R15及びR16は、同一に又は異なって水素原子、ヒドロキシ基、1,3-ジヒドロキシプロパン-2-イル基、メタンスルホニル基、N,N-ジメチルスルファモイル基及びC1-6アルキル基(該C1-6アルキル基は、アミノ基、モルホリニル基、ピペリジニル基、カルボキシ基、ヒドロキシ基及び式[4]に記載の置換基からなる群より同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)であるか、又は
R17及びR18は、同一に又は異なって水素原子又はメチル基であり、
R20は、水素原子又はメチル基である、請求項16に記載の化合物又はその薬学的に許容される塩。 - Aが、フェニル基又はヘテロ環基(該フェニル基及び該ヘテロ環基は、下記の置換基群Rcより同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)であり、
Rcは、メチル基(該メチル基は、カルボキシ基、ヒドロキシ基、カルバモイル基及び-N(R11)(R12)からなる群より同一に又は異なって選ばれる1個から2個の置換基で置換されてもよい。)、カルボキシ基及びヘテロ環基及び-CON(R15)(R16)であり、
R11及びR12は、同一に又は異なって水素原子、メチル基、n-ペンチル基、n-オクチル基、シクロプロピル基、シクロヘキシル基、ヒドロキシエチル基、N-メチルピペリジン-4-イル基、カルボキシメチル基、N,N-ジメチルアミノプロピル基及びアミノエチル基からなる群から選ばれる原子又は基であるか、又は
R11及びR12が結合する窒素原子と一緒になって形成する飽和の3員環から7員環は、アゼチジニル基、ピロリジニル基、ピペリジニル基又はモルホリノ基であり、
R15及びR16は、同一に又は異なって水素原子、メタンスルホニル基、N,N-ジメチルスルファモイル基、メチル基、エチル基又はn-プロピル基(該メチル基、エチル基又はn-プロピル基は、アミノ基、モルホリニル基、ピペリジニル基及びヒドロキシ基からなる群から選ばれる1個から2個の置換基で置換されてもよい。)である、請求項17に記載の化合物又はその薬学的に許容される塩。 - 請求項1から請求項18の化合物又はその薬学的に許容される塩を含有する医薬組成物。
- 請求項1から請求項18の化合物又はその薬学的に許容される塩を含有するGyrB/ParE阻害剤。
- 請求項1から請求項18の化合物又はその薬学的に許容される塩を含有する抗菌剤。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019133662A RU2019133662A (ru) | 2017-03-24 | 2018-03-23 | Производное 2(1h)-хинолинона |
AU2018239711A AU2018239711A1 (en) | 2017-03-24 | 2018-03-23 | 2(1h)-quinolinone derivative |
US16/496,066 US20210070747A1 (en) | 2017-03-24 | 2018-03-23 | 2(1h)-quinolinone derivative |
EP18772161.8A EP3604281A4 (en) | 2017-03-24 | 2018-03-23 | 2 (1H) -CHINOLINONE DERIVATIVE |
KR1020197024012A KR20190133667A (ko) | 2017-03-24 | 2018-03-23 | 2(1h)-퀴놀리논 유도체 |
CN201880019903.0A CN110446699A (zh) | 2017-03-24 | 2018-03-23 | 2(1h)-喹啉酮衍生物 |
CA3057431A CA3057431A1 (en) | 2017-03-24 | 2018-03-23 | 2(1h)-quinolinone derivative |
JP2019507047A JPWO2018174288A1 (ja) | 2017-03-24 | 2018-03-23 | 2(1h)−キノリノン誘導体 |
ZA2019/06699A ZA201906699B (en) | 2017-03-24 | 2019-10-10 | 2(1h)-quinolinone derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-060201 | 2017-03-24 | ||
JP2017060201 | 2017-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018174288A1 true WO2018174288A1 (ja) | 2018-09-27 |
Family
ID=63586553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/011913 WO2018174288A1 (ja) | 2017-03-24 | 2018-03-23 | 2(1h)-キノリノン誘導体 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210070747A1 (ja) |
EP (1) | EP3604281A4 (ja) |
JP (1) | JPWO2018174288A1 (ja) |
KR (1) | KR20190133667A (ja) |
CN (1) | CN110446699A (ja) |
AU (1) | AU2018239711A1 (ja) |
CA (1) | CA3057431A1 (ja) |
RU (1) | RU2019133662A (ja) |
WO (1) | WO2018174288A1 (ja) |
ZA (1) | ZA201906699B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022055926A1 (en) * | 2020-09-11 | 2022-03-17 | The Regents Of The University Of California | Compositions and methods for treating muscular dystrophies |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110885329B (zh) * | 2019-12-16 | 2020-12-15 | 诚达药业股份有限公司 | 一种1,7-萘啶衍生物的合成方法 |
CN113307768B (zh) * | 2021-04-29 | 2023-12-12 | 中国农业科学院兰州畜牧与兽药研究所 | 喹诺酮类衍生物及其制备方法和用途 |
CN115260176A (zh) * | 2022-09-02 | 2022-11-01 | 安徽农业大学 | 一种含噁唑基团的吡唑酰胺类衍生物及其制备方法和应用 |
Citations (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63301821A (ja) * | 1986-03-05 | 1988-12-08 | Otsuka Pharmaceut Co Ltd | 抗不整脈剤 |
WO2000040562A1 (fr) * | 1999-01-08 | 2000-07-13 | Japan Tobacco Inc. | Composes de 2-oxoquinoline et leurs utilisations medicinales |
WO2001052846A1 (en) | 2000-01-18 | 2001-07-26 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
WO2001052845A1 (en) | 2000-01-18 | 2001-07-26 | Vertex Pharmaceuticals Incorpoated | Gyrase inhibitors and uses thereof |
WO2002060879A2 (en) | 2000-12-15 | 2002-08-08 | Vertex Pharmaceuticals Incorporated | Bacterial gyrase inhibitors and uses thereof |
WO2003105846A1 (en) | 2002-06-13 | 2003-12-24 | Vertex Pharmaceuticals Incorporated | 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections |
WO2004103974A1 (ja) | 2003-05-23 | 2004-12-02 | Japan Tobacco Inc. | 置換2-オキソキノリン化合物およびその医薬用途 |
WO2005012292A1 (en) | 2003-01-31 | 2005-02-10 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
WO2005026149A1 (en) | 2003-09-13 | 2005-03-24 | Astrazeneca Ab | Pyrrol derivatives with antibacterial activity |
WO2005026162A1 (en) | 2003-09-05 | 2005-03-24 | Pfizer Inc. | Gyrase inhibitors |
WO2005089763A1 (en) | 2004-03-19 | 2005-09-29 | Warner-Lambert Company Llc | Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents |
WO2006022773A1 (en) | 2004-07-29 | 2006-03-02 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
WO2006038116A2 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
WO2006087543A1 (en) | 2005-02-18 | 2006-08-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
WO2006092599A2 (en) | 2005-03-04 | 2006-09-08 | Astrazeneca Ab | Pyrrole derivatives as dna gyrase and topoisomerase inhibitors |
WO2006092608A1 (en) | 2005-03-04 | 2006-09-08 | Astrazeneca Ab | Tricyclic derivatives of azetidine and pyrrole with antibacterial activity |
WO2007056330A1 (en) | 2005-11-07 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Benzimidazole derivatives as gyrase inhibitors |
WO2007071965A2 (en) | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines |
WO2007124617A1 (fr) | 2006-04-28 | 2007-11-08 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations |
WO2007148093A1 (en) | 2006-06-22 | 2007-12-27 | Prolysis Ltd. | Antibacterial compositions |
WO2008014307A2 (en) | 2006-07-26 | 2008-01-31 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase |
WO2008020227A2 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
WO2008020222A1 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Pyrrole derivatives with antibacterial activity |
WO2008020229A2 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
WO2008068470A1 (en) | 2006-12-04 | 2008-06-12 | Astrazeneca Ab | Antibacterial polycyclic urea compounds |
WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
WO2008152418A1 (en) | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Piperidine compounds and uses thereof |
WO2009027732A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | 5-6-bicyclic heteroaromatic compounds with antibacterial activity |
WO2009027733A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents |
WO2009061875A2 (en) | 2007-11-07 | 2009-05-14 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for producing aminobenzimidazole ureas |
WO2009074812A1 (en) | 2007-12-13 | 2009-06-18 | Prolysis Ltd | Antibacterial condensed thiazoles |
WO2009074810A1 (en) | 2007-12-13 | 2009-06-18 | Prolysis Ltd | Antibacterial compositions |
WO2009084614A1 (ja) | 2007-12-27 | 2009-07-09 | Daiichi Sankyo Company, Limited | イミダゾールカルボニル化合物 |
WO2009106885A1 (en) | 2008-02-26 | 2009-09-03 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof-211 |
WO2009147431A1 (en) | 2008-06-04 | 2009-12-10 | Astrazeneca Ab | Thiazolo [5, 4-b] pyridine and oxazolo [5, 4-b] pyridine derivatives as antibacterial agents |
WO2009147440A1 (en) | 2008-06-04 | 2009-12-10 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
WO2009147433A1 (en) | 2008-06-04 | 2009-12-10 | Astrazeneca Ab | Heterocyclic urea derivatives for the treatment of bacterial infections |
WO2009156966A1 (en) | 2008-06-25 | 2009-12-30 | Ranbaxy Laboratories Limited | Benzothiazoles and aza-analogues thereof use as antibacterial agents |
WO2010013222A1 (en) | 2008-07-30 | 2010-02-04 | Ranbaxy Laboratories Limited | Pyrrole carboxylic acid derivatives as antibacterial agents |
WO2010038081A2 (en) | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
WO2010067125A1 (en) | 2008-12-12 | 2010-06-17 | Astrazeneca Ab | 2- (piperidin-1-yl) -4-azolyl-thiazole-5-carboxylic acid derivatives against bacterial infections |
WO2010067123A1 (en) | 2008-12-12 | 2010-06-17 | Astrazeneca Ab | 2- (piperidin-1-yl) -4-heterocyclyl-thiazole-5-carboxylic acid derivatives against bacterial infections |
WO2010136817A1 (en) | 2009-05-29 | 2010-12-02 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
WO2010142978A1 (en) | 2009-06-08 | 2010-12-16 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
WO2011024004A1 (en) | 2009-08-26 | 2011-03-03 | Astrazeneca Ab | Heterocyclic urea derivatives useful for treatment of bacterial infection |
WO2011032050A2 (en) | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
WO2011121555A1 (en) | 2010-03-31 | 2011-10-06 | Actelion Pharmaceuticals Ltd | Antibacterial isoquinolin-3-ylurea derivatives |
WO2012045124A1 (en) | 2010-10-08 | 2012-04-12 | Biota Europe Ltd | Bacteria topoisomerase ii inhibiting 2-ethylcarbamoylamino-1, 3-benzothiazol-5-yls |
WO2012079532A1 (zh) * | 2010-12-17 | 2012-06-21 | 中国科学院上海药物研究所 | 一类双香豆素类化合物及其制备方法和用途 |
WO2012097269A1 (en) | 2011-01-14 | 2012-07-19 | Vertex Pharmaceuticals Incorporated | Pyrimidine gyrase and topoisomerase iv inhibitors |
WO2012098070A1 (en) | 2011-01-19 | 2012-07-26 | F. Hoffmann-La Roche Ag | Quinoline dyrk1 inhibitors |
WO2012125746A1 (en) | 2011-03-15 | 2012-09-20 | Trius Therapeutics Inc. | Tricyclic gyrase inhibitors |
WO2012131588A1 (en) | 2011-03-29 | 2012-10-04 | Actelion Pharmaceuticals Ltd | 3-ureidoisoquinolin-8-yl derivatives |
WO2013091011A1 (en) | 2011-12-21 | 2013-06-27 | Biota Europe Ltd | Heterocyclic urea compounds |
WO2014043272A1 (en) | 2012-09-12 | 2014-03-20 | Trius Therapeutics Inc. | Tricyclic gyrase inhibitors for use as antibacterial agents |
WO2015038661A1 (en) | 2013-09-11 | 2015-03-19 | Trius Therapeutics, Inc. | Tricyclic gyrase inhibitors |
WO2015050379A1 (ko) | 2013-10-01 | 2015-04-09 | 광주과학기술원 | 신규한 퀴놀리논 유도체 및 이의 용도 |
WO2016020836A1 (en) * | 2014-08-06 | 2016-02-11 | Novartis Ag | Quinolone derivatives as antibacterials |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK111387A (da) * | 1986-03-05 | 1987-09-06 | Otsuka Pharma Co Ltd | Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne |
RU2284325C2 (ru) * | 2003-12-17 | 2006-09-27 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе |
US20070287706A1 (en) * | 2006-05-18 | 2007-12-13 | Dickson John K Jr | Certain substituted quinolones, compositions, and uses thereof |
WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
EP2323660A2 (en) * | 2008-08-08 | 2011-05-25 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
-
2018
- 2018-03-23 EP EP18772161.8A patent/EP3604281A4/en not_active Withdrawn
- 2018-03-23 WO PCT/JP2018/011913 patent/WO2018174288A1/ja unknown
- 2018-03-23 CA CA3057431A patent/CA3057431A1/en not_active Abandoned
- 2018-03-23 RU RU2019133662A patent/RU2019133662A/ru not_active Application Discontinuation
- 2018-03-23 US US16/496,066 patent/US20210070747A1/en not_active Abandoned
- 2018-03-23 AU AU2018239711A patent/AU2018239711A1/en not_active Abandoned
- 2018-03-23 JP JP2019507047A patent/JPWO2018174288A1/ja not_active Withdrawn
- 2018-03-23 CN CN201880019903.0A patent/CN110446699A/zh active Pending
- 2018-03-23 KR KR1020197024012A patent/KR20190133667A/ko unknown
-
2019
- 2019-10-10 ZA ZA2019/06699A patent/ZA201906699B/en unknown
Patent Citations (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63301821A (ja) * | 1986-03-05 | 1988-12-08 | Otsuka Pharmaceut Co Ltd | 抗不整脈剤 |
WO2000040562A1 (fr) * | 1999-01-08 | 2000-07-13 | Japan Tobacco Inc. | Composes de 2-oxoquinoline et leurs utilisations medicinales |
WO2001052846A1 (en) | 2000-01-18 | 2001-07-26 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
WO2001052845A1 (en) | 2000-01-18 | 2001-07-26 | Vertex Pharmaceuticals Incorpoated | Gyrase inhibitors and uses thereof |
WO2002060879A2 (en) | 2000-12-15 | 2002-08-08 | Vertex Pharmaceuticals Incorporated | Bacterial gyrase inhibitors and uses thereof |
WO2003105846A1 (en) | 2002-06-13 | 2003-12-24 | Vertex Pharmaceuticals Incorporated | 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections |
WO2005012292A1 (en) | 2003-01-31 | 2005-02-10 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
WO2004103974A1 (ja) | 2003-05-23 | 2004-12-02 | Japan Tobacco Inc. | 置換2-オキソキノリン化合物およびその医薬用途 |
WO2005026162A1 (en) | 2003-09-05 | 2005-03-24 | Pfizer Inc. | Gyrase inhibitors |
WO2005026149A1 (en) | 2003-09-13 | 2005-03-24 | Astrazeneca Ab | Pyrrol derivatives with antibacterial activity |
WO2005089763A1 (en) | 2004-03-19 | 2005-09-29 | Warner-Lambert Company Llc | Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents |
WO2006022773A1 (en) | 2004-07-29 | 2006-03-02 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
WO2006038116A2 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
WO2006087543A1 (en) | 2005-02-18 | 2006-08-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
WO2006092599A2 (en) | 2005-03-04 | 2006-09-08 | Astrazeneca Ab | Pyrrole derivatives as dna gyrase and topoisomerase inhibitors |
WO2006092608A1 (en) | 2005-03-04 | 2006-09-08 | Astrazeneca Ab | Tricyclic derivatives of azetidine and pyrrole with antibacterial activity |
WO2007056330A1 (en) | 2005-11-07 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Benzimidazole derivatives as gyrase inhibitors |
WO2007071965A2 (en) | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines |
WO2007124617A1 (fr) | 2006-04-28 | 2007-11-08 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations |
WO2007148093A1 (en) | 2006-06-22 | 2007-12-27 | Prolysis Ltd. | Antibacterial compositions |
WO2008014307A2 (en) | 2006-07-26 | 2008-01-31 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase |
WO2008020227A2 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
WO2008020222A1 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Pyrrole derivatives with antibacterial activity |
WO2008020229A2 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
WO2008068470A1 (en) | 2006-12-04 | 2008-06-12 | Astrazeneca Ab | Antibacterial polycyclic urea compounds |
WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
WO2008152418A1 (en) | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Piperidine compounds and uses thereof |
WO2009027732A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | 5-6-bicyclic heteroaromatic compounds with antibacterial activity |
WO2009027733A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents |
WO2009061875A2 (en) | 2007-11-07 | 2009-05-14 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for producing aminobenzimidazole ureas |
WO2009074812A1 (en) | 2007-12-13 | 2009-06-18 | Prolysis Ltd | Antibacterial condensed thiazoles |
WO2009074810A1 (en) | 2007-12-13 | 2009-06-18 | Prolysis Ltd | Antibacterial compositions |
WO2009084614A1 (ja) | 2007-12-27 | 2009-07-09 | Daiichi Sankyo Company, Limited | イミダゾールカルボニル化合物 |
WO2009106885A1 (en) | 2008-02-26 | 2009-09-03 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof-211 |
WO2009147431A1 (en) | 2008-06-04 | 2009-12-10 | Astrazeneca Ab | Thiazolo [5, 4-b] pyridine and oxazolo [5, 4-b] pyridine derivatives as antibacterial agents |
WO2009147440A1 (en) | 2008-06-04 | 2009-12-10 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
WO2009147433A1 (en) | 2008-06-04 | 2009-12-10 | Astrazeneca Ab | Heterocyclic urea derivatives for the treatment of bacterial infections |
WO2009156966A1 (en) | 2008-06-25 | 2009-12-30 | Ranbaxy Laboratories Limited | Benzothiazoles and aza-analogues thereof use as antibacterial agents |
WO2010013222A1 (en) | 2008-07-30 | 2010-02-04 | Ranbaxy Laboratories Limited | Pyrrole carboxylic acid derivatives as antibacterial agents |
WO2010038081A2 (en) | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
WO2010067125A1 (en) | 2008-12-12 | 2010-06-17 | Astrazeneca Ab | 2- (piperidin-1-yl) -4-azolyl-thiazole-5-carboxylic acid derivatives against bacterial infections |
WO2010067123A1 (en) | 2008-12-12 | 2010-06-17 | Astrazeneca Ab | 2- (piperidin-1-yl) -4-heterocyclyl-thiazole-5-carboxylic acid derivatives against bacterial infections |
WO2010136817A1 (en) | 2009-05-29 | 2010-12-02 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
JP2012528137A (ja) * | 2009-05-29 | 2012-11-12 | アストラゼネカ アクチボラグ | 複素環式尿素誘導体およびそれらの使用方法 |
WO2010142978A1 (en) | 2009-06-08 | 2010-12-16 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
WO2011024004A1 (en) | 2009-08-26 | 2011-03-03 | Astrazeneca Ab | Heterocyclic urea derivatives useful for treatment of bacterial infection |
WO2011032050A2 (en) | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
WO2011121555A1 (en) | 2010-03-31 | 2011-10-06 | Actelion Pharmaceuticals Ltd | Antibacterial isoquinolin-3-ylurea derivatives |
WO2012045124A1 (en) | 2010-10-08 | 2012-04-12 | Biota Europe Ltd | Bacteria topoisomerase ii inhibiting 2-ethylcarbamoylamino-1, 3-benzothiazol-5-yls |
WO2012079532A1 (zh) * | 2010-12-17 | 2012-06-21 | 中国科学院上海药物研究所 | 一类双香豆素类化合物及其制备方法和用途 |
WO2012097269A1 (en) | 2011-01-14 | 2012-07-19 | Vertex Pharmaceuticals Incorporated | Pyrimidine gyrase and topoisomerase iv inhibitors |
WO2012098070A1 (en) | 2011-01-19 | 2012-07-26 | F. Hoffmann-La Roche Ag | Quinoline dyrk1 inhibitors |
WO2012125746A1 (en) | 2011-03-15 | 2012-09-20 | Trius Therapeutics Inc. | Tricyclic gyrase inhibitors |
WO2012131588A1 (en) | 2011-03-29 | 2012-10-04 | Actelion Pharmaceuticals Ltd | 3-ureidoisoquinolin-8-yl derivatives |
WO2013091011A1 (en) | 2011-12-21 | 2013-06-27 | Biota Europe Ltd | Heterocyclic urea compounds |
WO2014043272A1 (en) | 2012-09-12 | 2014-03-20 | Trius Therapeutics Inc. | Tricyclic gyrase inhibitors for use as antibacterial agents |
WO2015038661A1 (en) | 2013-09-11 | 2015-03-19 | Trius Therapeutics, Inc. | Tricyclic gyrase inhibitors |
WO2015050379A1 (ko) | 2013-10-01 | 2015-04-09 | 광주과학기술원 | 신규한 퀴놀리논 유도체 및 이의 용도 |
WO2016020836A1 (en) * | 2014-08-06 | 2016-02-11 | Novartis Ag | Quinolone derivatives as antibacterials |
Non-Patent Citations (14)
Title |
---|
ACS INFECT. DIS., vol. 1, 2015, pages 4 - 41 |
BIOORG. MED. CHEM. LETT., vol. 10, 2000, pages 821 - 826 |
BIOORG. MED. CHEM. LETT., vol. 14, 2004, pages 2863 - 2866 |
BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 4708 - 4714 |
BIOORG. MED. CHEM. LETT., vol. 19, 2009, pages 5302 - 5306 |
CLIN. INFECT. DIS., vol. 28, 1999, pages 352 - 364 |
DATABASE REGSITRY 31 January 2017 (2017-01-31), Database accession no. RN 2062082-09-9 * |
GEERS ET AL., ANTIMICROB. AGENTS. CHEMOTHER., vol. 33, 1989, pages 233 - 234 |
J. INFECT. CHEMOTHER., vol. 53, 2005, pages 349 - 356 |
J. MED. CHEM., vol. 44, 2001, pages 619 - 626 |
PHARMACOL. THER., vol. 60, 1993, pages 367 - 380 |
RADEVA, N. ET AL.: "Experimental Active-Site Mapping by Fragments: Hot Spots Remote from the Catalytic Center of Endothiapepsin", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 16, 27 July 2017 (2017-07-27), pages 7561 - 7575, XP055608859, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b00645 * |
See also references of EP3604281A4 |
TRENDS MICROBIOL., vol. 5, 1997, pages 102 - 109 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022055926A1 (en) * | 2020-09-11 | 2022-03-17 | The Regents Of The University Of California | Compositions and methods for treating muscular dystrophies |
Also Published As
Publication number | Publication date |
---|---|
CA3057431A1 (en) | 2018-09-27 |
CN110446699A (zh) | 2019-11-12 |
EP3604281A4 (en) | 2020-08-19 |
EP3604281A1 (en) | 2020-02-05 |
JPWO2018174288A1 (ja) | 2020-01-23 |
US20210070747A1 (en) | 2021-03-11 |
AU2018239711A1 (en) | 2019-11-07 |
RU2019133662A (ru) | 2021-04-26 |
ZA201906699B (en) | 2021-02-24 |
KR20190133667A (ko) | 2019-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10562916B2 (en) | Substituted quinoxalines as PDE-10 inhibitors | |
US10421731B2 (en) | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | |
US9556135B2 (en) | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | |
KR20200011965A (ko) | Map4k1의 신규한 억제제 | |
CA2787121C (en) | Aminopyridine derivatives as anti-malarial agents | |
WO2018174288A1 (ja) | 2(1h)-キノリノン誘導体 | |
RU2531274C2 (ru) | Феноксиметильные гетероциклические соединения | |
CA2729259A1 (en) | 1,2-disubstituted heterocyclic compounds | |
US20160168140A1 (en) | Heterocyclic compounds as antibiotic potentiators | |
CA2837199A1 (en) | Cinnoline compounds as inhibitor of lrrk2 kinase activity | |
JP6057907B2 (ja) | チアゾリジン誘導体又はその塩を有効成分とする医薬品 | |
JP5142730B2 (ja) | 抗感染薬としての新規なイソチアゾロキノロンおよび関連化合物 | |
US8877742B2 (en) | Compounds | |
JP5147237B2 (ja) | 抗感染剤としてのイソチアゾロキノロン類および関連化合物 | |
JPWO2004043936A1 (ja) | Plk阻害剤 | |
JP2022025116A (ja) | 抗菌性化合物 | |
US10035799B2 (en) | COMT inhibiting methods and compositions | |
WO2018172925A1 (en) | Inhibitors of dna gyrase for treatment of bacterial infections | |
JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
CN111527093B (zh) | 抗菌杂环化合物及其合成 | |
WO2017046603A1 (en) | Antibacterial compounds and new uses thereof | |
WO2023224893A1 (en) | Inhibitors of msba as antibiotics, pharmaceutical compositions, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18772161 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019507047 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197024012 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3057431 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018772161 Country of ref document: EP Effective date: 20191024 |
|
ENP | Entry into the national phase |
Ref document number: 2018239711 Country of ref document: AU Date of ref document: 20180323 Kind code of ref document: A |